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Critical limb ischemia (CLI), a severe form of peripheral arterial disease, results in 
chronic pain, tissue loss, and often requires amputation. Therapeutic angiogenesis 
using autologous cells holds great promise for CLI treatment, while minimizing 
ethical and safety issues. However, this approach is often limited by the cell 
numbers at harvest and issues with prolonged in vitro expansion. Our group has 
recently developed a monocyte-derived cell type named “Blood-derived 
Angiogenic Cells” (BDACs). Using pulsed macromolecular crowding (MMC), it 
was possible to generate clinically relevant numbers of 10 to 40 million functional 
cells from 100 ml of human peripheral blood within 5 days. Furthermore, BDACs 
have been shown to be pro-angiogenic, both in vitro and in vivo.  
Despite the promising pro-angiogenic potential of BDAC, its therapeutic efficacy 
has not been demonstrated in an animal model for CLI. This thesis therefore aims 
to prove the hypothesis that BDACs promote recovery from hind limb ischemia in 
mice by promoting angiogenesis. 
Before proceeding to the animal model, further characterization of the generation 
of BDACs and their mode of action were performed. Firstly, we compared the 
BDAC generation protocol with and without the use of MMC. It is demonstrated 
here that MMC not only more than doubled the cell number, but also increased the 
percentage of spindle-shaped cells, angiogenic markers expression, and the pro-
angiogenic capacity in vitro. Therefore, MMC was used for BDAC generation for 
the rest of the experiments.  
Following the in vitro characterization, the efficacy of BDAC was examined using 
a pre-clinical model of murine hind limb ischemia. Two cohorts of this in vivo 
model were performed comprising unilateral ligation of the external iliac artery. 
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The initial publication (Blocki, Wang et al., 2015) demonstrated that a single 
injection of BDACs rescued most limb tissues from ischemia-induced necrosis. 
Magnetic resonance angiography (MRA) studies demonstrated that BDAC 
treatment accelerated reperfusion in the ischemic limbs. Histologically, BDAC-
treated animals showed reduced fibrosis, attenuated adipose-replacement, and 
reduced neutrophil infiltration.  
In the second cohort of this animal model, we compared the effect of BDACs and 
undifferentiated monocytes. However, due to a change in animal supplier, a 
different mouse substrain was delivered, which only became evident 
retrospectively. This substrain showed a high intrinsic revascularization capacity, 
and therefore gave surprisingly little tissue necrosis, offering a very narrow window 
for comparisons between treated and untreated animals. As a result, magnetic 
resonance angiography analysis showed similar vessel volumes for all groups. 
Laser Doppler Imaging produced similar results. The drastic difference between 
the two mouse substrains were examined and highlighted in a separate chapter.  
Whilst at the vascularization level, it was not possible confirm the earlier described 
differences, BDACs accelerated functional recovery of the ligated hind limb when 
compared to undifferentiated monocytes or vehicle control. This unexpected 
observation led to a new question: Can BDACs directly influence muscle 
regeneration through mechanisms independent of vascularization?  
Our study validated the therapeutic potential of BDAC and its pro-angiogenic 
capacity in a disease model. Future work is needed to investigate other mechanisms 
for BDACs’ therapeutic effect, besides angiogenesis.   
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Critical limb ischemia—an unmet medical need  
Peripheral artery diseases (PAD) are vascular occlusion diseases resulting from 
atherosclerosis or thromboembolic lesions (Annex, 2013). They affect the 
normal function of the arteries in the extremities and other organs (Norgren et 
al., 2007). A systematic review (Fowkes et al., 2013) estimated that more than 
200 million people worldwide had PAD in 2010, a 23.5% increase compared to 
a decade earlier. Among them, 54.8 million patients were estimated to be from 
Southeast Asia alone (Fowkes et al., 2013). The strikingly high prevalence has 
led scientists to refer to PAD as a “global pandemic” (Hirsch & Duval, 2013; 
Lim, 2013). 
Critical limb ischemia (CLI) is the most advanced stage of PAD, when the 
occlusion of blood vessels is so severe that there is insufficient blood perfusion 
to the distal tissues (Becker et al., 2011). Clinically, CLI is defined by a 
persistent ischemic rest pain and/or ulceration/gangrene of the foot, caused by 
arterial occlusive disease (Becker et al., 2011). The incidence of CLI was 
estimated to be 220 new cases per million per year (Norgren et al., 2007). 
Moreover, the number of CLI patients is expected to grow. The two main CLI 
risk factors are aging and diabetes, which continue to affect an increasing 
percentage of the global population. The number of combined critical limb 
ischemia patients in Western Europe and North America was estimated at 5.8 
million in 2010, and is expected to increase to more than 8.5 million by 2030 
(SAGE, 2010a, 2010b).  
CLI patients show lower quality of life compared to PAD patients, and no-
option CLI patients have even significantly lower quality of life scores 
(Sprengers et al., 2010). The low life quality of CLI patients is associated with 
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the physical pain, which is most often described as “stabbing”, “hot-burning”, 
“tender”, or “shooting” (Rüger et al., 2008). The ischemic rest pain often 
intensifies at night and affects the patients’ sleep (Norgren et al., 2007). Another 
hallmark symptom of CLI is ulceration and gangrene at the toes and foot, due 
to insufficient nutrient supply, and hence impaired healing capacity (Becker et 
al., 2011). 
The distress in CLI patients is not only from the physical pain, but also from 
physiological factors. CLI results in limited physical function, which leads to 
compromised mobility and autonomy (Treat-Jacobson et al., 2002). CLI 
patients also experience stress and anxiety due to the poor prognosis. According 
to the TASC II consensus for PAD management (Norgren et al., 2007), 30% of 
CLI patients may require amputation one year after their primary treatment, 
while another 20% continue to suffer from CLI.  
Mechanism of critical limb ischemia 
In most cases, CLI involves multi-level arterial occlusion (Hirsch et al., 2006). 
For example, the occlusion often occurs at aortoiliac and femoropopliteal 
segments, or femoropopliteal and tibial segments (Illustration 1). However, it 
may also occur in parallel arterial segments, for example superficial and deep 
femoral artery segments (Hirsch et al., 2006). The multi-level nature of the 
occlusion reduces the effectiveness of collateral vessels to compensate for the 
blood flow (Hirsch et al., 2006). The occlusion decreases the blood flow in the 
distal capillary networks. When the perfusion drops below the level required to 
maintain tissue viability, tissue death progresses, ultimately leading to 
amputation, if left without intervention (Hirsch et al., 2006).  




Illustration 1. The vasculature of the lower extremities. The vasculature is divided into three 
parts from proximal to distal: Aortoiliac (inflow area), femoropopliteal, and tibial (outflow area). 
a.: Artery. Adapted by permission from Macmillan Publishers Ltd: Nature Review Cardiology 
Annex (2013), copyright 2013.  
Conventional interventions 
The main objectives of CLI treatment are pain relief, ulcer care, limb 
preservation, and improvement of quality of life and survival (Norgren et al., 
2007). Besides treatments for symptom relief, such as pain control and wound 
management, as well as lifestyle changes such as smoking cessation, there are 
a few available options aimed at improving blood perfusion and eventual limb 
salvage. Several important considerations influence the choice of treatment, 
including the urgency of the patient’s situation, the presence of comorbidity, 
and the anatomy of affected arteries (Hirsch et al., 2006).  
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Endovascular or surgical revascularization is currently the standard treatment 
for CLI (Hirsch et al., 2006). Endovascular revascularization is a minimally 
invasive technique to repair vascular lesions. With the patient under local 
anaesthesia, a catheter is advanced to the lesion site through a small incision, 
placing a small cutter, a compressed balloon, a stent, or a coil at the disease site, 
to expand the occluded vessel lumen (Cooley, 2014). Surgical revascularization, 
on the other hand, usually involves an open surgery to access the occluded 
vessel. The most common approach is bypass surgery, where an autologous or 
prosthetic graft is used to bypass the occlusion. In general, surgical bypass has 
good patency, depending on the location of the bypass (Hirsch et al., 2006). 
However, endovascular revascularization is the strategy of choice for elder 
patients or patients with comorbidities, who may not tolerate well an open 
surgery (Hirsch et al., 2006; Slovut & Sullivan, 2008). The main drawback of 
endovascular revascularization is reduced long term patency and that more 
frequent restenosis compared to surgical revascularization. The efficacy of the 
endovascular approach further decreases with length, presence of multiple and 
defuse lesions, and comorbidities such as diabetes and renal failure (Tendera et 
al., 2011). In an increasing number of cases, a hybrid approach combining both 
endovascular and surgical revascularization is used (Sluvot & Sullivan, 2008).  
For patients with medical conditions that make them unsuitable for 
revascularization surgeries, or patients who underwent a failed 
revascularization attempt, there are a few alternative treatment options. Spinal 
cord stimulation (SCS) applies electric pulses through implanted electrodes in 
the epidural space, and stimulates specific regions of the spinal cord (Mailis-
Gagnon, Furlan, Sandoval, & Taylor, 2004).  It leads to vessel vasodilation and 
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pain relief (Naoum & Arbid, 2013). Another treatment option, intermittent 
pneumatic compression (IPC), mechanically increases blood flow using an 
inflatable sleeve around the patient’s limb connected to a pneumatic pump. The 
sleeve is inflated and deflated at regular intervals, generating pulses of pressure 
around the limb. Both SCS and IPC are not included in international guidelines 
due to insufficient evidence of efficacy (Setacci et al., 2011). Lastly, many CLI 
patients are given antiplatelet drugs, lipid-lowering therapy, beta-blockers, or 
statin to control the risk of cardiovascular event (Hirsch et al., 2006; Norgren et 
al., 2007; Slovut & Sullivan, 2008; Rooke et al., 2011).   
When revascularization attempts fail, and other treatment options prove 
ineffective, amputation is used as the last resort to reduce pain and to save the 
patient’s life (Slovut & Sullivan, 2008). For patients with non-reconstructable 
CLI, 40% undergo primary amputation within the first 6 months (Hirsch et al., 
2006). Amputation is considered as the primary treatment in late stage or life-
threatening ischemia, or in the presence of serious infection (Hirsch et al., 2006). 
Primary amputation is also considered for patients with significant foot necrosis, 
poor ambulation, severe rest pain, or a very limited life expectancy (Hirsch et 
al., 2006). Among the patients who underwent below-knee amputation, only 40% 
achieved full mobility after 2 years, 15% required above-knee amputation, 15% 
required contralateral amputation, and 30% died (Norgren et al., 2007). One-
year survival after above-knee amputation is only 50.6% (reviewed by Slovut 
& Sullivan, 2008).  
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Limitations in current treatment options 
Despite the advancement in endovascular technology, a significant percentage 
of patients with severe CLI do not qualify for endovascular revascularization 
because of the anatomy of the lesion, while their condition may not permit open 
surgery due to anaesthesia risk, comorbidities, or wound healing problem.  
For the patients who are able to undergo revascularization, a large percentage 
of them need to be readmitted to the hospital after the initial procedure (Annex, 
2013; Slovut & Sullivan, 2008). This eventually leads to secondary amputation 
in 60% of these patients (Norgren et al., 2007). Casey, Hernandez-Boussard, 
Mell, and Lee (2011) reported that 1-year readmission rate is 55.4% after 
endovascular revascularization. A more recent study of endovascular patients 
(Reed et al., 2016) reported 14% readmission within 30 days, and 56% 
readmission within the follow-up period (median: 381 days). In the PREVENT 
III clinical trial, McPhee et al. (2013) reported that 24.4% of the 866 patients 
were readmitted within 30 days of discharge following infrainguinal bypass.  
Even when the revascularization procedure is successful, not all patients 
experience clinical improvement. Taylor et al. (2007) found that only 44.4% of 
331 surgical revascularization patients studied can be considered to have 
achieved a successful outcome, if other parameters are considered besides graft 
patency (1-year limb salvage, wound healing, 1-year ambulation capacity, 6-
month survival). Simons et al. (2010) reported that among the 78% patients with 
patent infrainguinal bypass graft, 10% did not show improvement of symptoms 
and were therefore a clinical failure.  
The dismal outcome of conventional CLI therapies suggests that 
revascularization of major blood vessels may not be sufficient to rescue 
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downstream tissue and to enable functional recovery. Several reasons may 
account for this observation. Firstly, there may be distal, diffuse occlusions in 
small blood vessels that are not repairable through revascularization. Secondly, 
the pre-existing damage in distal tissue cannot be rescued by restoration of 
perfusion alone. Thirdly, the feeding capillary bed may have been permanently 
damaged, and therefore unable to supply the local tissue. These issues of local 
perfusion and tissue regeneration are not addressed by conventional treatment. 
Novel treatment options that are able to resolve diffuse occlusion in small blood 
vessels and protect downstream ischemic tissue would be highly desirable. 
Therapeutic angiogenesis, an approach that promises to address these issues, is 
described in the following section.  
Therapeutic angiogenesis: Fundamental concepts 
Therapeutic angiogenesis, the generation of new blood vessels using molecular 
and cell therapy, has generated much interest in treating ischemic diseases. It 
can be achieved through angiogenesis, arteriogenesis, and vasculogenesis. The 
rest of this chapter will introduce these basic concepts in therapeutic 
angiogenesis (Illustration 2), followed by a review of the different approaches 
to apply therapeutic angiogenesis in critical limb ischemia.  
Angiogenesis 
Angiogenesis is the sprouting of new blood vessels from existing ones 
(Folkman, 1996). It builds up and maintains the vital circulatory network that 
supplies nutrients and oxygen to various tissues, and removes metabolic wastes. 
Angiogenesis is an essential process in embryonic development (reviewed by 
Herbert & Stainier 2011), and later plays an important role in wound healing 
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and tissue regeneration. Aberrant angiogenesis is a main factor in pathologic 
conditions such as ischemic diseases and malignancy (reviewed by Herbert & 
Stainier 2011).  
Angiogenesis is a multi-step process fine-tuned by a complex network of factors. 
In peripheral artery diseases (PAD), the initial driving force of angiogenesis is 
hypoxia, or oxygen deficiency in tissues. This leads to the activation of 
transcription factor hypoxia inducible factor 1 (HIF-1) (Ke & Costa, 2006; 
Semenza, 1998). HIF-1 consists of two subunits, HIF-1α and HIF-1β. HIF-1α 
is rapidly degraded under normoxia, but under hypoxia, it remains stable, and 
is therefore able to dimerize with HIF-1β to regulate more than 100 target genes, 
including vascular endothelial growth factor (VEGF) and matrix 
metalloproteinases (MMPs) (Ke & Costa, 2006).  
In the first stage of angiogenesis, vessel homeostasis is disrupted (Herbert & 
Steinier, 2011). This process is regulated by the angiopoietin 1 (Ang1), its 
antagonist Ang2, and their receptor Tie2 (Augustin, Koh, Thurston, & Alitalo, 
2009). When Ang2 binds with Tie2 and disrupts Ang1-Tie2 association, the 
vessel is destabilized (Herbert & Stainier, 2011). A small fraction of endothelial 
cells (ECs) will then be activated to become “tip cells”. The tip cells migrate or 
sprout towards chemotaxis signals, bringing ECs called “stalk cells” behind 
them (Herbert & Stainier, 2011). EC tip cells are characterized by their 
numerous filopodia. They are able to detect chemical gradient, such as VEGF 
gradient, and direct the sprouting of blood vessels.  
Vascular endothelial growth factor (VEGF) is another key factor in this 
migration step. EC tip cells have a high amount of VEGF receptor 2 (VEGFR2). 
When VEGF binds with VEGFR2, it stimulates EC migration, proliferation, and 
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survival (Carmeliet, De Smet, Loges, & Mazzone, 2009). VEGF also plays a 
role in macrophage recruitment (reviewed by Murdoch, Giannoudis, & Lewis, 
2004). Overexpression of VEGF in mice leads to more and leaky vessels, while 
co-expression of VEGF and Ang1 results in increased vessel diameter but not 
abnormally high vessel permeability (Thurston et al., 1999).  
The next stage is anastomosis. Upon reaching the destination vessel, the tip cells 
lose their mobility and fuse with the vessel ECs (Herbert & Stainier, 2011). 
These newly formed EC sprouts also start to develop a lumen and to recruit 
mural cells, which consist of smooth muscle cells and pericytes. The mural cells 
are essential for vessel stability and maintenance. Platelet-derived growth factor 
B (PDGFB) and transforming growth factor-β1 are the key factors in mural cells 
mobilization (Herbert & Stainier, 2011). PDGFB secreted by ECs induces mural 
cell adhesion by binding to the PDGF receptor β (PDGFRβ) on mural cells 
(Gaengel, Genove, Armulik, & Betsholtz, 2009). Inversely, Ang1 expressed on 
mural cells induces vessel stabilization (Gaengel et al., 2009).  
Arteriogenesis 
Angiogenesis is the most well studied mechanism of vasculature remodelling, 
largely driven by its role in tumour progression. However, in the case of 
ischemic disease, it has been pointed out that another process, arteriogenesis, 
may play an important role (reviewed by Schaper & Buschmann, 1999).   
It has long been observed that the collateral arteries expand after chronic 
coronary artery occlusion, but the first quantitative animal study is probably by 
W. Schaper and Vandesteene (1967). They observed that after occlusion of the 
coronary artery in dogs, collateral vessels increased in diameter and wall 
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thickness, and were able to sustain blood perfusion and to avoid myocardial 
infarction. This phenomenon of collateral growth was named arteriogenesis 
(Arras et al., 1998). 
The driving force for arteriogenesis is increased shear stress in the vessel lumen 
(van Royen et al., 2001), which in turn activates a series of molecular pathways, 
including the ion channel TRPV4, the Pho-pathway, and the nitric oxide 
synthase (NOS) pathway (Fung & Helisch, 2012; Troidl & Schaper, 2012). One 
important signalling molecule is nitric oxide (NO), which is able to diffuse 
through the endothelial cell layer and reach the smooth muscle cells, leading to 
vessel vasodilatation (Troidl & Schaper, 2012). Monocytes and macrophages 
also play an important role in arteriogenesis (Fung & Helisch, 2012). 
Endothelial-derived monocyte chemoattractant protein 1 (MCP-1) attracts 
monocytes and activates resident macrophages, which in turn secret cytokines 
necessary for collateral growth (Troidl & Schaper, 2012).  
Vasculogenesis  
Vasculogenesis originally refers to the in situ formation of a vascular plexus 
through angioblast differentiation (Risau et al., 1988). During embryonic 
development, angioblasts and hematopoietic precursor cells form aggregates 
called blood islands, which then fuse and further develop into the primitive 
vascular system (Risau et al., 1988). This concept has later been generalized to 
refer to the process of circulating progenitor cells differentiating into endothelial 
cells and forming new blood vessels. The idea of post-natal vasculogenesis is 
largely driven by the discovery of endothelial progenitor cells (EPCs), which 
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were shown to incorporate into the neo-vasculature in vivo (Asahara et al., 
1999). EPCs will be discussed in further details later in this chapter.  
The distinction between angiogenesis and vasculogenesis is not definitive, and 
both processes may contribute at the same time to blood vessel development 
(Ribatti, Vacca, Nico, Roncali, & Dammacco, 2001). The term “vasculogenesis” 
is loosely used in literature and sometimes incorrectly.  
 
Illustration 2. Angiogenesis, arteriogenesis, and vasculogenesis. EPC: Endothelial 
progenitor cell.  
Gene therapy for CLI treatment 
Therapeutic angiogenesis aims to increase blood perfusion in ischemic tissue 
through the three mechanisms discussed above. Two approaches, gene and cell 
therapy, have both produced promising results (Setacci et al., 2011).  
Following the discovery of VEGF, the earlier attempts of therapeutic 
angiogenesis adopted the molecular approach. Besides VEGF, the most studied 
angiogenic agents are fibroblast growth factor (FGF), hepatocyte growth factor 
 Introduction  
13 
 
(HGF), and the transcription factor HIF-1α. They are administrated mostly as 
naked DNA plasmids, or in some cases loaded on a viral or non-viral vector. So 
far, despite promising results in animal models and small scale clinical trials, 
larger clinical trials have produced mixed results (reviewed by Annex, 2013; 
Davies, 2012).  
The only completed phase III clinical trial, TAMARIS, studied the efficacy of 
non-viral FGF treatment in 525 CLI patients. DNA plasmids encoding human 
FGF1 were intramuscularly injected in the treatment group. Despite successful 
phase I and II trials, the phase III study unfortunately showed no improvement 
in terms of preventing amputation or death, with a major amputation/death rate 
of 33% in the placebo group and 36% in the treatment group (Belch et al., 2011).    
At the time of writing, a few phase III clinical trials are about to start or ongoing, 
including the clinical trial for VM202, a plasmid encoding two isoforms of HGF 
(Kibbe et al., 2016). The outcome is yet to be seen.    
Cell therapy for CLI treatment 
Given the variation in the clinical outcome of gene therapy, a lot of attention 
has turned towards cell therapy for CLI. The majority of clinical trials use 
patient autologous cells, either from bone marrow or from peripheral blood. 
Most of them adopt intramuscular administration, although intra-arterial 
administration or a combination of both have also been used.   
Bone marrow aspirate concentrate or bone marrow mononuclear cells 
Bone marrow was the first cell source used in CLI clinical trials. It is usually 
aspirated from the iliac crest of the patient or donor, and requires mainly local 
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anaesthesia. Bone marrow volumes ranging from 50 to 500 ml per patient have 
been used in clinical trials. 
Two methods have been used to process the harvested bone marrow. Bone 
marrow aspirate concentrate (BMAC) is produced by simple centrifugation of 
the aspirate, which concentrates all cells as well as platelets from the bone 
marrow and reduces the total injection volume. Bone marrow mononuclear cells 
(BMMC) are purified from bone marrow aspirate either through density 
gradient centrifugation or through a filter system, and comprise mostly 
mononuclear cells. Some studies include an ex vivo expansion process to 
increase the cell numbers before treatment.  
Bone marrow is the most established cell source, and is used in all completed 
or ongoing phase III clinical trials for CLI cell therapy. The earliest randomized, 
double-blind, placebo-controlled, multicentre trial for CLI cell therapy 
conducted by Biomet Biologics, using BMAC, has been ongoing since 2010, 
and is expected to be completed in June 2016. There is so far no update about 
the trial outcome. Another phase III clinical trial, conducted by Harvest 
Technologies, used BMAC from 240 ml of bone marrow for intramuscular 
administration. The trial was completed in December 2015, and the outcome is 
yet to be released. The Ixmyelocel-T system developed by Aastrom Biosciences 
requires only 50 ml of bone marrow, but needs an in vitro expansion of 12 days 
to obtain enough cells for the treatment. Their phase III clinical trial named 
REVIVE, was started in 2012, but discontinued in March 2013 due to difficulty 
in patient enrolment. Cesca Therapeutics recently obtained FDA approval for a 
phase III trial (CLIRST) using BMAC, which is expected to complete in March 
2018.  
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Besides the phase III clinical trials, more than 20 case reports or clinical trials 
have been published using BMMC or BMAC. Among the seven placebo-
controlled clinical trials identified, three studies reported significant reduction 
of amputation (Idei et al., 2011; Napoli et al., 2008; Prochazka et al., 2010), one 
reported prolonged time-to-failure (major amputation, death, doubling of 
wound area, or new gangrene) (Powell et al., 2012), and one reported 
improvement in rest pain and ulcer healing (Walter et al., 2011). The Harvest 
trial by Iafrati et al. (2011), as well as the largest clinical trial to date, the 
JUVENTAS trial (Teraa et al., 2015) with 160 patients, has not revealed 
significant improvement with bone marrow-derived cell treatment compared to 
the control group.  
In one clinical trial, allogenic bone marrow MSCs were used to treat 10 CLI 
patients (Gupta et al., 2013). Compared to the control group, there was a 
significant improvement of ankle-brachial index, but not in other clinical 
parameters. 
Peripheral blood mononuclear cells 
Compared to bone marrow, harvesting cells from peripheral blood has the 
advantage of being less invasive and more easily accessible. Moreover, the use 
of apheresis allows for harvesting peripheral blood mononuclear cells (PBMCs) 
without depleting other blood components. However, peripheral blood has a 
lower mononuclear cell concentration compared to the bone marrow. Therefore, 
the majority of studies using PBMCs administer granulocyte colony-stimulating 
factor (G-CSF) to the patients for 5 days, in order to mobilize stem cells into 
peripheral blood from the bone marrow. Typically, a blood volume of 300 to 
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500 ml is drawn per treatment. In most studies, the whole mononuclear cell 
fraction is used, while several clinical trials used only the CD34+ or CD133+ 
populations, which are enriched in progenitor cells. CD34 and CD133 have also 
been used to identify endothelial progenitor cells from the peripheral blood, as 
will be described in the next section.  
So far there has been no phase III clinical trial using peripheral blood as a cell 
source for CLI treatment. More than ten case reports or clinical trials have been 
published using PBMCs or PBMC-derived cells. Among the seven controlled 
studies, three of the studies used G-CSF (Huang et al., 2007; El Ansary, et al., 
2014; Ozturk et al., 2012). Szabó et al. (2013) only drew 250 ml of blood per 
patient, but required ex vivo culture for 5 days. De Angelis et al. (2015) used 
120 ml of blood per treatment for up to three treatments, and concentrated the 
cells using a filtration system.  
Four studies reported significant reductions in amputation rate compared to 
control group (De Angelis et al., 2015; El Ansary, AlAbden, Halim, Shafy, & 
Hafeez, 2014; Huang et al., 2005; Szabo et al., 2013). Ozturk et al. (2012) 
reported significant improvement in CD34+ cell treated patients in terms of 
ankle-brachial pressure index, pain relief, pain-free walking distance and ulcer 
healing, but not in avoiding amputation. Of the other two studies using either 
CD34+ (Losordo et al., 2012) or CD133+ (Raval et al., 2014) sorted PBMCs, a 
positive trend was observed in terms of reducing amputation rate, but was not 
significant. Raval et al. (2014) had a very small patient population (3 treated, 7 
placebo control) because many patients did not have enough CD133+ cells for 
treatment even after G-CSF stimulation. It is still inconclusive if CD34-selected 
cells have a stronger therapeutic potential than whole PBMCs.  
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Monocyte-derived cell types and macrophages in therapeutic 
angiogenesis 
Many novel cell types have shown promising results in pre-clinical models for 
CLI. The majority of these emerging cellular approaches are of monocyte or 
macrophage origin. This is hardly surprising, since monocyte-derived cells and 
macrophages have long been known to play an important role in angiogenesis 
and vasculature remodelling.  
Monocytes and macrophages are heterogenous populations with various origins 
and functions. “Resident” macrophages, such as alveolar macrophages, 
Langerhans cells, microglia, and Kupffer cells, are developed in the embryonic 
stage and are maintained in adult tissues; “passenger” leukocytes, such as 
monocytes, are derived from myeloid progenitors from the bone marrow 
(reviewed by Gomez Perdiguero et al., 2015). In chronic inflammation, the 
origin of macrophages depends on the tissue microenvironment as well as the 
pathological condition. Tumour-associated macrophages (TAM), for example, 
consist of a mixture of resident macrophages and monocyte-derived 
macrophages (reviewed by Lahmar et al., 2016). In myocardial infarction, on 
the other hand, most of the infiltrating macrophages are found to be monocyte-
derived (Swirski et al., 2009). 
Conventionally, the primary function of macrophages was considered to be 
defending tissue against pathogens. It has become clear that monocytes and 
macrophages have a much wider spectrum of functions. One important 
observation was the role of tumour-associated macrophages (TAMs), 
macrophages that infiltrate malignant tissue. At the turn of this century, a 
surprising correlation was observed between the amount of TAMs and poor 
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prognosis in the majority of cancer cases (reviewed by Pollard, 2004). TAMs 
are recruited to the tumour site by tumour-derived cytokines, such as CCL2 and 
MCP-1 (reviewed by Sica, Schioppa, Mantovani, & Allavena, 2006). TAMs 
adapt their role to different stages of tumour development and the 
microenvironment, with a pro-inflammatory profile at tumour initiation, while 
adopting a pro-angiogenesis, immunomodulatory role towards later stages of 
tumour progression (reviewed by Schmieder, Michel, Schonhaar, Goerdt, & 
Schledzewski, 2012).  
To cover the range of macrophage phenotypes, the most widely used system 
defines two extrema of macrophage activation states: classically activated 
macrophages (M1) and alternatively activated macrophages (M2), mirroring the 
nomenclature of Th1 and Th2 T helper cells. Generally speaking, M1 
macrophages produce high levels of pro-inflammatory cytokines, reactive 
oxygen species, and nitric oxide; induce cytotoxicity and exert a strong 
microbicidal effect. On the other hand, M2 macrophages have high phagocytic 
and scavenging capacity, are immunoregulatory, and promote tissue 
remodelling (reviewed by Sica & Mantovani, 2012). M1 polarization is induced 
by interferon-γ (IFN-γ), granulocyte-macrophage colony-stimulating factor 
(GM-CSF), lipopolysaccharide (LPS), and tumour necrosis factor (TNF) 
(reviewed by Martinez & Gordon, 2014). The M2 macrophages are slightly 
more complex. Originally, Interleukin (IL)-4 and IL-13, the main products of 
Th2 cells, were considered the activators of M2 macrophages. These 
macrophages are now termed M2a, and several other M2 subsets have been 
proposed. M2b macrophage activation is induced by Fc receptors and immune-
complexes, and M2c macrophages are induced by glucocorticoids. Besides that, 
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IL-10 and macrophage colony-stimulating factor (M-CSF) can also induce M2 
polarization (reviewed by Martinez & Gordon, 2014).  
The M1-M2 system is a simplified representation that originated from in vitro 
culture. The in vivo environment is far more complex. Multiple stimuli may be 
present simultaneously, leading to a mixture of macrophage populations, whose 
characteristics are not fully captured by the M1-M2 axis (thus the emergence of 
the M2 subsets). With increasing understanding of the macrophage activation 
pathways, the M1-M2 system is likely to expand even further.  
M2, rather than M1 macrophages, have been attributed with a strong angiogenic 
capacity. TAMs, for example, are found to have M2 macrophage functions 
(reviewed by Sica et al., 2006). A correlation between TAM presence and 
tumour angiogenesis has been reported in leiomyosarcoma (Espinosa et al., 
2011), human colon carcinoma (Badawi, Abouelfadl, El-Sharkawy, El-Aal, & 
Abbas, 2015), ameloblastoma (Guzman-Medrano et al., 2012), animal models 
of breast cancer (Lin et al., 2006; Liu et al., 2015; Rego, Helms, & Dreau, 2014), 
and skin carcinoma (Linde et al., 2012). M2 macrophages were shown to 
increase angiogenesis in subcutaneously implanted matrigel plugs compared to 
M1 macrophages (Jetten et al., 2014). Growth factors, such as FGF-2 and 
placental growth factor, were found to account for the pro-angiogenic effect of 
M2 macrophages (Jetten et al., 2014).  
Following that, different subsets of monocytes and macrophages have been 
found to contribute to angiogenesis, including endothelial progenitor cells, 
fibrocytes, Tie2-expressing monocytes, and Blood-derived Angiogenic Cells 
(BDACs). The following section will focus on their in vivo and in vitro 
identification, the possible mechanisms by which they participate in 
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angiogenesis, and their potential application in therapeutic angiogenesis for 
critical limb ischemia.  
Endothelial progenitor cells   
Asahara et al. (1999) demonstrated that adult bone marrow-derived progenitor 
cells participate in neovasculature formation in tumours as well as in ischemic 
conditions. They named these cells endothelial progenitor cells (EPCs) and 
proposed that they are able to differentiate into endothelial cells and undergo 
postnatal vasculogenesis. It still remains to be answered as to what is the exact 
identity of EPCs, and how to identify them in vivo. CD34, a hematopoietic stem 
cell marker, was first used to identify EPCs. Asahara et al. (1997) first reported 
that the CD34-positive population of adult peripheral blood mononuclear cells 
is enriched in EPCs. On a fibronectin-coated surface, CD34-selected cells 
adopted a spindle-shape and formed cord-like structures. After 7 days of in vitro 
culture, a percentage of these cells expressed endothelial cell markers CD31, 
Tie2, and E-selectin. When implanted in vivo, they were found in close 
association with neovasculature (Asahara et al., 1997).  
There was much disagreement in the definition and marker expression of EPCs. 
CD34 is the most commonly used marker to isolate EPCs from PBMCs, and is 
used in a number of clinical trials (Kawamoto et al., 2009; Dong et al., 2013; 
Losordo et al., 2012). Besides CD34, Sca-1 (Takahashi et al., 1999), 
Tie2/VEGFR2 (Asahara et al., 1999), and CD133 (Raval, et al., 2014) have also 
been used to identify EPCs. However, none of these markers are endothelial cell 
or EPC specific. In practice, EPCs are often selected by adherence to collagen I 
(Ingram et al., 2004; Case et al., 2007) or fibronectin (Kalka, et al., 2000; 
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Kawamoto et al., 2001) coated surfaces. In most clinical trials, the whole PBMC 
fraction is used without purification (Huang et al., 2005; Lara-Hernandez et al., 
2010; Capiod, et al., 2008; Huang et al., 2005; Ansary et al., 2012; Ozturk et 
al., 2012; De Angelis et al., 2015).  
It has become increasingly clear that "EPCs" are actually a heterogeneous 
population, and the “EPCs” in one publication is not necessarily comparable 
with the EPC population described in another. The majority of what are believed 
to be EPCs may be monocyte-derived macrophages with an alternatively 
activated M2 phenotype (Medina et al., 2011; Yoder et al., 2007). These cells 
have been named early EPC (eEPC), colony-forming unit EC (CFU-EC), or 
myeloid angiogenic cells (Case et al., 2007; Hur et al., 2004; Medina et al., 
2011). They are charaterized by a spindle-shaped morphology, limited 
proliferation capacity, and expression of myeloid lineage surface markers such 
as CD45, CD14, and the M2 marker, CD163 (Hur et al., 2004; Rehman, Li, 
Orschell, & March, 2003; Yoder et al., 2007). Functionally, they are reported 
to phagocytose (Yoder et al., 2007; Medina et al., 2011), and do not incoporate 
into neovasculature when implanted in vivo (Yoder et al., 2007).  
The other much rarer population is named late outgrowth endothelial cells 
(OECs), or endothelial colony-forming cells (ECFCs) (Case et al., 2007; Yoder 
et al., 2007). They have a typical cobblestone morphology, and appear much 
later in culture (Hur et al., 2004). They are truly able to differentiate into 
endothelial cells and have a high proliferation potential (Hur et al., 2004; Yoder 
et al., 2007). They express stronger endothelial markers such as VE-cadherin 
(CD144), vWF, and CD31 (Hur et al., 2004; Ingram et al., 2004; Yoder et al., 
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2007). When implanted in vivo, late OECs integrate into host vasculature and 
form chimeric vessels (Yoder et al., 2007).  
Both early EPCs and late OECs have been shown to increase angiogenesis when 
implanted in ischemic animal models (Asahara et al., 1997; Hur et al., 2004; 
Yoder et al., 2007), but probably through different mechanisms. While late 
OECs participate directly in the formation of new blood vessels, early EPCs 
have been reported to secrete angiogenic factors in a paracrine manner, and thus 
promote angiogenesis (Urbich et al., 2004; Medina et al., 2011) 
Fibrocytes  
Similar to EPCs, fibrocytes are also spindle-shaped cells generated from 
peripheral blood. They were first generated by Bucala, Spiegel, Chesney, Hogan, 
and Cerami (1994), who observed adherent, fibroblast-like cells expressing 
collagen and vimentin in a subcutaneously implanted wound chamber. 
Fibrocytes have been identified in vivo using co-expression of CD45, CXCR4, 
and collagen I (Mitsuhashi et al., 2015; Phillips et al., 2004). CD34 was 
originally used as a fibrocyte marker in vivo (Bucala et al., 1994) but is no 
longer widely used, probably due to its close link to EPCs (see section above). 
When cultured in vitro, fibrocytes were found to express extracellular matrix 
(ECM) proteins such as collagen I, collagen III, collagen VI, fibronectin, and 
vimentin (Bianchetti et al., 2012; Bucala et al., 1994; Curnow et al., 2010). At 
the same time, they express hematopoietic markers CD45, CD34, CD11b, CD86, 
MHC class II molecules, as well as alternatively activated macrophage markers 
CD163, CD204, and CD206 (Abe, Donnelly, Peng, Bucala, & Metz, 2001; 
Bianchetti et al., 2012; Bucala et al., 1994; Chesney, Bacher, Bender, & Bucala, 
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1997). However, they do not express surface markers for monocytes (CD14), 
T-cells (CD3), and B-cells (CD19) (Bucala et al., 1994). Phillips et al. (2004) 
reported a shift in fibrocyte marker expression with time. After 2 to 3 weeks of 
in vitro culture after adherence selection, they observed an upregulation in 
alpha-smooth muscle actin expression, while CD34 and CD45 expression was 
reduced.  
Fibrocytes can be generated from CD14-enriched PBMCs, but not from a 
CD14-depleted population (Abe et al., 2001; Curnow et al., 2010). Usually, 
PBMCs are seeded onto plastic surfaces in medium supplemented with 20% 
serum. After overnight attachment, the non-adherent cells are removed and the 
adherent cells left to grow for up to two weeks, when most of them will adopt a 
typical spindle-shaped morphology and express fibrocyte markers (Bucala et al., 
1994); fibrocyte differentiation in vitro is inhibited by serum amyloid P, a main 
component of serum (D. Pilling, Buckley, Salmon, & Gomer, 2003). Culturing 
PBMCs in serum-free medium accelerates the two week fibrocyte generation 
protocol to 5 days (Darrell Pilling, Fan, Huang, Kaul, & Gomer, 2009). 
Although the resulting cell population has similar surface marker expression as 
cells generated with serum-containing medium, there are some differences in 
their gene expression profile (Curnow et al., 2010).  
Fibrocytes participate in wound healing by migrating to wound sites and 
producing ECM proteins (Bucala et al., 1994; Abe et al., 2001). They also play 
an important role in pathological fibrosis (Phillips et al., 2004). Another 
unexpected role of fibrocytes is to act as antigen presenting cells and stimulate 
T-cell activation (Chesney et al., 1997). Fibrocytes are further reported to 
secrete factors important in wound healing and angiogenesis, including MMP-
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9, bFGF, CM-CSF, IL-8, M-CSF, and VEGF, and have been shown to promote 
endothelial cell proliferation and migration (Hartlapp et al., 2001). More 
recently, Mitsuhashi et al. (2015) found that fibrocyte-like cells contribute to 
tumour drug resistance to bevacizumab, an anti-angiogenic drug inhibiting 
VEGF. They identified fibrocyte-like cells in vivo by co-expression of CD45, 
collagen I, and CXCR4. These cells were recruited through the CXCR4/CCL12 
axis and rescued tumour angiogenesis by secreting FGF2.  
There are conflicting evidences on the application of fibrocytes in therapeutic 
angiogenesis. Hartlapp et al. (2001) reported that fibrocytes and fibrocyte-
conditioned media promoted angiogenesis in vivo in a matrigel implant. Kao et 
al. (2011) showed that fibrocytes injected through the tail vail accelerated mice 
skin wound healing through multiple mechanisms including angiogenesis. 
Geiger et al. (2015) locally injected fibrocytes-derived exosomes and 
demonstrated accelerated wound healing in diabetic mice, although it is not 
clear if angiogenesis played an important role. On the other hand, an interesting 
publication by Li et al. (2014) suggested that circulating fibrocytes inhibited 
angiogenesis in the proliferation phase of wound healing, while inhibited vessel 
regression in the remodelling phase, thereby stabilizing vessel structure and 
delaying wound healing. It is worth noting that different from the other groups, 
Li et al. (2014) used freshly isolated fibrocytes by depleting B/T cells and 
monocytes without any in vitro culture.  It is not known if the resulting cells are 
comparable with fibrocytes reported in other studies, and if the in vitro culture 
process had an effect on the cells’ properties and thus their therapeutic effect.  
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Tie2-expressing monocytes  
Tie2-expressing monocytes (TEMs) were first described by De Palma et al. 
(2003). They observed a Tie2+CD45+CD11b+ population both in mouse bone 
marrow and peripheral blood. About 1-2% of total leukocytes in peripheral 
blood and 3-6% of leukocytes in bone marrow are TEMs (De Palma et al., 2008). 
These Tie2-positive leukocytes migrated to the tumour periphery and were 
found to be associated with blood vessels (De Palma, Venneri, Roca, & Naldini, 
2003). Besides the defining marker Tie2, TEMs were also reported to express 
Sca-1, CD14, CD16, CD11c, and CD45, while lacking the expression of 
endothelial markers and progenitor markers such as VEGFR2, CD133, CD146, 
and CD34 (De Palma et al., 2005; Lewis, De Palma, & Naldini, 2007). Different 
from EPCs and fibrocytes, TEMs have been only described in vivo, and no ex 
vivo expansion of TEMs has been attempted yet.  
The main research focus on TEMs has been their potential use as a cancer 
biomarker and anti-angiogenesis therapy target. Selective ablation of Tie2-
expressing cells inhibited tumour growth and led to tumour necrosis (De Palma 
et al., 2003; De Palma et al., 2005). In vitro, TEMs increased EC spheroid 
sprouting and EC network formation compared to Tie2- monocytes (Coffelt et 
al., 2010). Ang2, overexpressed in a number of tumours, induced increased 
expression of pro-angiogenic factors by TEMs, including MMP9, VEGFA, 
TNF-α, COX-2, MRC1, and WNT5A (Coffelt et al., 2010). TEMs isolated from 
murine mammary tumours promoted angiogenesis in subcutaneously-implanted 
tumours (Lewis et al., 2007).  
The only report to date using TEMs for therapeutic angiogenesis in an animal 
model was by Patel et al. (2013). They demonstrated that critical limb ischemia 
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patients had 9 times more TEMs in circulating CD14+ monocytes compared to 
age-matched controls, and the TEM level returned to normal after resolution of 
CLI. In a murine hind limb ischemia model, targeted Tie2 silencing impaired 
limb revascularization, while forced expression of Tie2 in murine CD11b+ bone 
marrow-derived macrophages stimulated revascularization (Patel et al., 2013). 
Moreover, CLI patient-derived TEMs resulted in 80% limb salvage in nude 
mice compared to 0% in the control group (Patel et al., 2013). However, no 
further publication followed up on this interesting result.  
Blood-derived angiogenic cells (BDAC) 
Despite the promising results from cell-based therapeutic angiogenesis, there 
are a few limitations in current approaches. The most commonly used cell 
source, bone marrow, involves an invasive extraction procedure. On the other 
hand, peripheral blood is an easily accessible autologous cell source, but 
contains a lower concentration of therapeutic cells and often requires G-CSF 
mobilization. A lot of current research focuses on ex vivo expansion of cells 
from peripheral blood to generate sufficient cell numbers with potent 
therapeutic capacity.  
Our laboratory recently generated a novel cell type using such an approach. We 
named them Blood-derived Angiogenic Cells, or BDACs in short. BDACs are 
derived from monocytes in human peripheral blood, and share many 
characteristics with pericytes, the supporting cells around small blood vessels. 
Using a technique called macromolecular crowding (MMC), we are able to 
generate clinically relevant numbers of BDACs within 5 days from a regular 
400 ml blood sample (Blocki, Wang et al., 2015). Like early EPCs and 
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fibrocytes, BDACs are adherent, spindle-shaped cells, and express 
hematopoietic markers as well as Tie2 (Blocki, Wang et al., 2015). However, 
we demonstrated that BDACs have a unique marker expression panel that 
differentiates them from other monocyte-derived cells and macrophages (Blocki, 
Wang et al., 2015). To our knowledge, there are not yet other research groups 
reporting a BDAC-like cell type with the same marker expression.  
More importantly, we have shown that BDACs are pro-angiogenic in vitro using 
a matrigel network formation model and a collagen sprouting model (Blocki, 
Wang et al., 2015). BDACs also promoted angiogenesis in glioma xenograft in 
mice and resulted in increased tumour size (Blocki, Wang et al., 2015). A more 
detailed description of our prior work done on BDACs will be covered in the 
introduction of the next chapter.  
Knowledge gap to be addressed 
The pro-angiogenic properties of BDACs and the efficient generation protocol 
make BDACs a promising candidate for CLI treatment. However, so far, 
BDACs’ therapeutic effect has not been shown in a disease model. It is 
unknown if the implantation of BDACs will promote angiogenesis in vivo, 
reduce ischemic tissue damage, and accelerate function recovery. Investigation 
of their therapeutic potential and pro-angiogenesis capacity in a pre-clinical 
model is essential for their future clinical application, as well as for 
understanding their mode of action in vivo.  
Secondly, we have routinely used MMC in the generation of BDACs, and 
observed that MMC significantly increased the cell yield. However, the effect 
of MMC of the characteristics and functions of the generated cells is not fully 
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studied. A comparative study would be necessary to justify the use of MMC in 
potential therapeutic applications.  
Thirdly, we have previously focused on the interaction between BDACs and 
endothelial cells. It is not known how BDACs interact with other cell types 
present in CLI environment, and if BDACs have other functions besides 
promoting angiogenesis.  
Lastly, towards the end of this thesis, we made the observation that the animals’ 
capacity to recover from hind limb ischemia differs greatly from one substrain 
to another, even though they were all of the BALB/c strain. The effect of 
BALB/c substrain selection on murine hind limb ischemia model is not 
described in literature. Investigation into the substrain differences may provide 
insight into factors that are important for post-ischemia recovery. By 
highlighting this substrain-related issue, we hope that it would help other 
researchers to avoid potential pitfalls in animal selection.  
This thesis will attempt to answer the above questions in order to provide a 
better understanding of BDACs and to demonstrate their therapeutic potential.  
 
  




The objective of this thesis is to demonstrate the therapeutic potential of BDACs 
using an animal model for CLI, the murine hind limb ischemia model, with the 
following hypothesis: 
BDACs promote recovery from hind limb ischemia in mice by promoting 
angiogenesis. 
a) BDAC treatment accelerates functional recovery and reduces tissue 
loss from surgically induced hind limb ischemia in mice.  
b) BDAC treatment accelerates or increases revascularization in the 
ischemic limb.   
In Chapter 1, before proceeding to the animal model, I will first discuss a 
comparative study of BDAC generation, with and without the use of MMC. The 
number and morphology of cells generated using both methods, their marker 
expression, and their performance in angiogenesis assays in vitro will be 
compared.  
After establishing the necessity of MMC in BDAC generation, Chapter 2 
investigates the effect of BDAC treatment in a murine hind limb ischemia model 
in vivo. We attempted to answer the question if BDACs were able to promote 
angiogenesis in hind limb ischemia model, and thereby improve tissue 
vascularization leading to limb salvage.  
Chapter 3 discusses the unexpected substrain difference we observed in our two 
cohorts of animal experiments.  
Finally, Chapter 4 explores alternative mechanisms besides angiogenesis 









Chapter 1: A comparative study of the 
effect of macromolecular crowding on 
Blood-derived Angiogenic Cells generation 
  




Blood-derived Angiogenic Cells (BDACs) were first generated in our 
laboratory by Dr Anna Blocki as an attempt to improve the fibrocyte generation 
protocol using macromolecular crowding (MMC). However, the resulting cells 
turned out to have different properties from conventional fibrocytes, or other 
monocyte-derived cell types described in the literature. BDACs have a different 
marker expression panel compared to EPCs, fibrocytes, and TEMs. In addition, 
BDACs also lack typical macrophage functions of phagocytosis and antigen 
presentation. However, we observed a strong pro-angiogenic capacity of 
BDACs both in vitro and in vivo. From an easily accessible source, peripheral 
blood, BDACs can be produced with relatively high efficiency within 5 days of 
ex vivo culture. These features make BDACs a promising candidate for 
therapeutic angiogenesis for ischemic diseases, and in particular, for critical 
limb ischemia.  
One of the main differences in the generation protocol of BDACs and other 
monocyte-derived cell types is the use of MMC pulsing during the first day of 
culture. We previously observed that MMC pulsing not only increased the 
number of cells generated but also the percentage of spindle-shaped cells. 
Whether MMC is also important for the cells’ characteristics and function 
remains unknown. The objective of this chapter is to quantitatively compare the 
cells generated with and without the use of MMC, not only in terms of cell 
number and morphology, but also in terms of surface marker expressions and 
pro-angiogenic properties in vitro. However, first of all, I will introduce the 
concept of macromolecular crowding and the generation and characteristics of 
BDACs.  




In the physiological setting, both the cellular interior and the extracellular space 
contain abundant macromolecules at total concentrations of 50-400 mg/ml 
(Minton, 2001). In the intracellular space, macromolecules typically occupy 20-
30% of the total volume, which corresponds to concentrations of 200-300 
mg/ml (Ellis, 2001). High concentrations of macromolecules are also found in 
the extracellular environment such as the extracellular matrix (Minton, 2001). 
Even blood plasma is significantly “crowded”, with a protein concentration of 
about 80mg/ml (Minton, 2001).  
Besides soluble proteins, macromolecules range from nucleic acids, 
polysaccharides, to large cytoskeleton fibres. Regardless of whether they 
participate in any biochemical reactions, there are always non-specific repulsion 
forces between all molecules in a solution, since no two molecules can occupy 
the same place at the same time (Ellis, 2001). This results in a much confined 
space for the other molecules to move around and for biochemical reactions to 
take place. The extent of “confinement” exerted by the macromolecules on a 
molecule of interest (the “probe”) depends on their relative sizes (Illustration 3). 
This effect is called the excluded volume effect, or macromolecular crowding 
(MMC) (Ellis, 2001). In contrast, the in vitro culture system used in biological 
research usually only contains a low concentration of macromolecules of 1-10 
mg/ml (Ellis, 2001). This drastic difference will likely affect the rates and 
equilibria of biochemical reactions (Zimmerman & Harrison, 1987). 
  




Illustration 3. Illustrating excluded volume effect and macromolecular crowding. 
Macromolecules are represented by solid black spheres that occupy 25% of the total space, a 
typical value in physiological conditions. When a probe molecule of diameter r tries to enter the 
space, it has only a limited accessible volume (represented in green). Both the volume occupied 
by the macromolecules, and the space up to a distance r from the macromolecules, are excluded 
from the probe molecule. Therefore, with the same distribution of macromolecules, a small 
probe molecule (left) has more accessible volume compared to a large probe molecule (right). 
The illustration is shown in two dimensions instead of three dimensions for simplicity.   
The effect of MMC has been extensively studied on the molecular level. Two 
main effects of MMC have been revealed: increasing the effective concentration 
and reducing the rate of diffusion (reviewed by Zimmerman & Minton, 1993). 
It has been shown to promote protein folding (Batra, Xu, Qin, & Zhou, 2009; 
Tokuriki et al., 2004; Zhou, 2013), DNA replication (Akabayov, Akabayov, Lee, 
Wagner, & Richardson, 2013; Jarvis, Ring, Daube, & von Hippel, 1990), and 
extracellular matrix (ECM) assembly (Dewavrin et al., 2015; Zeiger, Loe, Li, 
Raghunath, & Van Vliet, 2012). However, at the cellular level, the effect of 
MMC is a complex topic that still needs to be elucidated. Rashid et al. (2014) 
demonstrated through TRITC-tagged macromolecules that mesenchymal stem 
cells internalize macromolecules through pinocytosis into mitochondria and 
lysosomes. MMC has been shown to enhance MSC adipogenesis and ECM 
deposition (Ang et al., 2014). There is still a lot of potential of using MMC as 
a biotechnology platform in in vitro cell culture systems.  
 Chapter 1: A comparative study of the effect of MMC on BDACs generation  
34 
 
Introducing BDACs: Blood-derived Angiogenic Cells 
What are BDACs? 
BDACs are monocyte-derived cells generated from human peripheral blood 
using MMC pulsing. BDACs share many characteristics with other monocyte-
derived cell types, such as EPCs, fibrocytes, and TEMs. On the other hand, 
BDACs also resemble non-mesenchymal pericytes in terms of their marker 
expression and their close association with ECs. We have previously 
demonstrated that BDACs are pro-angiogenic in vitro, by stabilizing EC 
network on matrigel and by promoting the sprouting of EC spheroid in collagen 
I gels (Blocki, Wang et al., 2015). Furthermore, BDACs promoted tumour 
angiogenesis in a glioma transplant model in mice (Blocki, Wang et al., 2015). 
In addition, BDACs have relatively high generation efficiency and a marker 
expression panel that distinguishes BDACs from their monocyte-derived 
cousins (Table 1). 
The generation of BDACs using MMC 
BDACs are derived from the adherence-selected cell fraction of PBMCs on 
fibronectin-coated surface, similar to the EPCs or fibrocyte generation protocol 
used in a number of studies (Bucala et al., 1994; Case et al., 2007; Ingram et al., 
2004). However, only in the generation of BDACs, the PBMCs are cultured 
under MMC conditions during the first day of cell seeding. We used a mixture 
of two sucrose polymers, Ficoll 70 and Ficoll 400. Compared to other MMCs 
such as dextran sulfate and polystyrene-4-sulfonate, Ficoll cocktail resulted in 
optimal extracellular matrix deposition (Chen, Loe, Blocki, Peng, & Raghunath, 
2011). The optimized concentration of the Ficoll cocktail gives a fraction 
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volume occupancy of 17%, which mimics the physiological condition (Chen, et 
al., 2011). At day 2, non-adherent cells are removed by a single, gentle 
aspiration, and fresh medium without MMC is then added. The cells are allowed 
to grow for another 4 days (Illustration 4). Using this protocol, we are able to 
generate 100-400 x 103 cells per ml of blood. Based on CD206 expression, more 
than 70% of these cells are BDACs (Blocki, Wang et al., 2015). In comparison, 
a typical protocol for EPC generates about 35x103 cells per ml of blood (Kalka 
et al., 2000). Therefore, we are able to generate enough BDACs for treatment 
from one regular blood drawing of 400 ml. In patients where drawing of large 
amount of blood is undesirable, leukapheresis may be a safe alternative, 
although it is yet to be tested for BDAC generation. 
 
Illustration 4. Generation of BDACs. Peripheral blood mononuclear cells (PBMCs) are 
isolated from human peripheral blood by Ficoll gradient centrifugation. They are then seeded 
in DMEM supplemented with 10% FBS, 1% p/s, and an optimized mix of two macromolecular 
crowders, Ficoll70 and Ficoll400. After the cells attach overnight, the non-adherent cells and 
the MMC medium are aspirated and replaced with fresh MMC-free medium. The cells are 
allowed to grow for another 4 days while they differentiate into spindled-shaped BDACs. 
BDACs are distinct from other monocyte-derived cell types in terms of marker 
expression and function 
Despite their similarities with other monocyte-derived cell types, BDACs have 
a unique marker profile that we have previously characterized (Figure 1, Blocki, 
Wang et al., 2015). Derived from the myeloid lineage, early EPCs, fibrocytes, 
TEMs, and BDACs share the expression of pan-leukocyte marker CD45 and 
monocyte/macrophage marker CD11b. Early EPCs are similar to BDACs in 
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terms of marker expression, but while EPCs have a comparable phagocytic 
activity to macrophages (Yoder et al., 2007; Medina et al., 2011), BDACs have 
a very weak phagocytic activity that is at similar levels as non-myeloid cells 
(Blocki, Wang et al., 2015). Fibrocytes are defined by their capacity to produce 
ECM such as collagen I (Bucala et al., 1994; Abe et al., 2001), which BDACs 
do not produce. Fibrocytes have also been reported to express MHC II 
molecules and have antigen-presenting function (Chesney, et al., 1997), while 
BDACs do not express HLA-DR. (Table 1) 
 
Figure 1. BDAC has a unique marker expression profile. Flow cytometry for Blood-derived 
Angiogenic Cells (BDACs) for mesenchymal stromal cell, endothelial cell, and leukocyte 
markers. BDACs were generated from human peripheral blood mononuclear cells (PBMCs) 
with the use of macromolecular crowding during the first day of culture. Cells were harvested 
at day 5, incubated with respective antibodies, and fixed with 1% paraformaldehyde. Control 
cells were incubated with the isotype control. Cells with fluorescent signals higher than 97% of 
the control were considered positive. Results are expressed as mean ±standard deviation (sd). 
Data published in Blocki, Wang et al. (2015). 
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Table 1. Comparing eEPC, fibrocytes, TEM, and BDAC 
 eEPC Fibrocytes TEM BDACm 
Mesenchymal stromal cell markers 
CD29  Highe  98% 
CD105 74%a Highe  95% 
Collagen I  Highf  Low 
α-SMA  Highf  Low 
desmin  Lowe  High 
Endothelial cell markers 
CD31 34-92%a, b Lowe Lowj Moderate-
high 
CD144 9-35%a, b   3% 
CD146 57%a  0%k 1% 
VEGFR-2 12-99%a, b  2%k 98% 
vWF 67% a Lowe    Low 
Leukocyte markers 
CD11b  Highe, g >85%j, k 93% 
CD13  Highe 95%k 98% 
CD14 99%a Lowe, g 89%k 56% 
CD19  Lowe 3%k 1% 
CD34 8%b Variablee, g 22%l 0% 
CD45 96-98%a, b  Highe, g 99%j, k 98% 
CD83 Lowc        4% 
CD133 7%b Low e  0% 
CD206 82%c Variablee, h  90% 
HLA-DR  Highi  1% 
PM-2K  Lowe  High 
Tie2   100% High 
Other characteristics 
Phagocytosis Higha, c   Low 
Yield/106 PBMC 5X104 d 1~5X103 f 2~7X104 k 1~2X105 
eEPC: early endothelial progenitor cell. TEM: Tie2-experssing monocytes. BDAC: Blood-derived 
Angiogenic Cell. 
BDACs are pro-angiogenic in vitro and promote angiogenesis in vivo in a 
mouse tumour implantation model  
BDACs do share an important function with the other types of monocyte-
derived cells–namely, they promote angiogenesis. We have previously 
demonstrated the pro-angiogenic capacity of BDACs in two different 
                                                 
aYoder et al. (2007); bCheng et al. (2013); dMedina et al. (2011); dHur et al. (2004); ePiling et al. (2009); 
fAbe et al. (2001); gBucala et al. (1994); hBianchetti et al. (2011); iChesney et al. (1997); jDe Palma et al. 
(2005); kVenneri et al. (2007); lMurdoch et al. (2007); mBlocki, Wang et al. (2015) 
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angiogenesis assays in vitro (Blocki, Wang et al., 2015). When co-cultured with 
endothelial cells on matrigel, BDACs co-localized with EC networks. Although 
there was no significant difference in terms of network formation, EC networks 
without BDACs broke down faster over time, and at 16 hours, there were 
significantly more EC networks with BDAC co-culture. We also showed and 
that BDACs enhanced the spouting of EC spheroids embedded in collagen I gel 
(Blocki, Wang et al., 2015). To form these EC spheroids, ECs were seeded 
overnight into non-adherent round-bottomed 96-well plate. The spheroids were 
then suspended in collagen I gel solution with or without BDACs. The 
suspension was allowed to solidify. Over the next two to three days, EC 
spheroids formed sprouts into the collagen I gel. BDACs were observed both at 
the centre of the EC spheroids as well as along the EC-formed sprouts. In 
sprouts from BDAC-free conditions, ECs often broke away from the tip of the 
sprouts, while with BDAC co-culture, the spheroids formed longer and 
continuous sprouts. When the total sprouts length was measured at day 3, 
BDACs were shown to increase EC sprouting in a dose dependent matter; the 
condition with the highest number of BDACs produced the most EC sprouts.  
Lastly, the pro-angiogenic effect of BDACs was verified in vivo in a tumour 
implant model (Blocki, Wang et al., 2015). Human glioma cells, U87, alone 
(control) or mixed with BDACs were subcutaneously injected into nude mice, 
which led to local tumour formation. The tumours were harvested and 
histologically analyzed after 8 days. Tumours containing BDACs had 30-50% 
more vasculature compared to the control condition (based on vWF and CD31 
staining).  
 Chapter 1: A comparative study of the effect of MMC on BDACs generation  
39 
 
BDACs’ role in angiogenesis seems to be directing endothelial cell sprouting 
and stabilizing EC-formed networks, rather than differentiating into EC. 
Although BDACs alone could form spheroids, they disintegrated rapidly 
(Blocki, 2012). In time-lapse videos of matriel assay (Blocki, 2012) and 
spheroid sprouting assay (data not shown), we observed that the majority of 
BDACs moved along EC networks and accumulated at junctions/spheroid 
centres, rather than contributing directly to EC network/sprout formation.   
Summary and scope of Chapter 1 
BDACs generated in our lab have a unique marker expression profile and pro-
angiogenic capacity in vitro. We would like to investigate if these properties are 
a result of the in vitro culture process, especially the use of MMC pulsing on 
the first day.  
Following the BDAC protocol, cells were generated either with (+MMC) or 
without (-MMC) the use of MMC. The resulting cells’ morphology, number, 
marker expression, and performance in phagocytosis and angiogenesis assays 
in vitro were compared.  
The conception of the BDAC protocol and the characterization of BDACs 
covered in the introduction above are work done by Dr Anna Blocki for her PhD 
thesis (Blocki, 2012), where I helped to perform the immunocytochemistry and 
flow cytometry work for the marker profile of BDACs during my Master’s 
thesis. The following experimental work and data analysis are performed by 
myself for the presently submitted PhD thesis.   
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Materials and methods 
Cell culture 
All cell culture was performed at 37°C in a humidified incubator in an 
atmosphere of 5% CO2. BDAC isolation and culture were performed in 
accordance to the National University of Singapore Institutional Review Board 
regulations. BDACs were generated following the protocol first published in 
Blocki, Wang et al. (2015). In brief, peripheral blood mononuclear cells 
(PBMCs) were isolated from human peripheral blood by Ficoll gradient 
centrifugation (Ficoll-PaqueTMPLUS, 17-1440-02, GE Healthcare, Uppsala, 
Sweden) following the manufacturer’s protocol. To generate BDACs, the 
PBMCs were seeded at 0.5-0.6 million cells/cm2 on bovine fibronectin (F1141, 
Sigma-Aldrich, Saint Louis, USA)-coated cell culture plates in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), 1% penicillin/streptomycin (p/s), and a Ficoll cocktail consisting of 
Ficoll PM70 (17-0310-50, GE Healthcare) at 37.5 mg/ml and Ficoll PM400 (17-
0300-50, GE Healthcare) at 25 mg/ml. The Ficoll was dissolved in warm 
medium immediately before use, and sterile filtered with a 0.22 μm filter (16532, 
Satorius Stedim Biotech GmbH, Göttingen, Germany). The cells were allowed 
to adhere overnight. After one day, the medium was replaced with fresh DMEM 
(10% FBS, 1% p/s), and adherent cells were cultured for another 4 days.  
Human placenta pericytes (Pl-Prc) (C-12980, PromoCell, Heidelberg, Germany) 
were cultured in Pericyte Growth Medium (C-28040, PromoCell). Human 
umbilical vein endothelial cells (HUVECs) (C2519A, Lonza, Basel, 
Switzerland) were cultured in endothelial cell growth medium, which consists 
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of Endothelial Basal Medium-2 (CC-3156, Lonza) supplemented with 
Endothelial Growth Medium-2 SingleQuots (CC-4176, Lonza).  
Macrophages were differentiated from human peripheral blood mononuclear 
cells in RPMI 1640 medium (HyClone, SH30027.01, Thermo Scientific) 
supplemented with 10% FBS and 100 ng/ml macrophage colony-stimulating 
factor (M-CSF) (300-25, Peprotech, Rocky Hill, USA) for 7 days, with a 
medium change at day 3. 
BDACs proliferation assay and Ki67 staining 
BDAC isolation and culture were performed as described above on 24-well 
plates. At 6 hours, 1 day, 3 days, and 5 days after seeding, the cell layers were 
washed three times with Hank's Balanced Salt Solution (HBSS) or phosphate-
buffered saline (PBS), and fixed with methanol at -20°C for 10 minutes. Fixed 
cell layers were stained with 4',6-diamidino-2-phenylindole (DAPI) for nuclear 
DNA. Whole mount 2x images were taken for each well with a Cool Snap HQ 
camera and a Nikon TE2000 microscope equipped with an automated, 
motorized stage. The images were analyzed and the number of nuclei counted 
with Metamorph Imaging System Software (Molecular Devices).  
For Ki67 staining and quantification, the cell layers were co-stained with DAPI 
and Ki67, or with DAPI and secondary antibody conjugate control only. The 
imaging was performed at Nikon Imaging Centre, Singapore Bioimaging 
Consortium. Whole mount images were taken for each well with a Cool Snap2 
Interline CCD camera, attached to a Nikon N-STROM microscope equipped 
with an automated, motorized stage. The images were analyzed and the number 
of nuclei counted with NIS-Elements software (Nikon Instruments). The 
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number of cells with positive Ki67 staining were counted manually. The 
percentage of cells positive for Ki67 staining for each well was calculated as 
total number of Ki67-positive cells divided by total number of cell nuclei.   
Immunocytochemistry 
Cells were cultured on 24-well plates and fixed with methanol at -20°C for 10 
minutes. Fixed cell layers were blocked at room temperature for 1 hour in 3% 
(w/v) bovine serum albumin (BSA) solution in PBS. The BSA solution was then 
replaced by primary antibody diluted in PBS and incubated for 90 minutes at 
room temperature or for 16 hours at 4°C. Subsequently, the cells were washed 
three times with PBS, shaking for 5 minutes during each wash, before 
incubating in an antibody cocktail containing DAPI and the respective 
secondary antibodies at room temperature for 30 minutes. Cells were again 
washed three times with PBS before being examined under an IX71 inverted 
fluorescence microscope (Olympus) and a CP70 microscope camera (Olympus). 
Flow cytometry 
Cells were harvested, washed, and resuspended in 1% FBS in PBS at 60,000 to 
200,000 cells per 50 µl per sample. The samples were incubated with respective 
antibodies or isotype controls for 1 hour at 4°C. At the end of the incubation, 
the samples were washed once with 1% FBS and then fixed in 500 µl of ice-
chilled 1% formaldehyde. The samples were analyzed using a flow cytometer 
(Cyan ADP flow cytometer, Beckman Coulter). Cells with fluorescent intensity 
stronger than 97% of isotype control were counted as positive staining.  




PBMCs (cultured following BDAC protocol with or without MMC), 
macrophages, or HUVECs were seeded on 24-well plates. The cell medium was 
removed and 200 µl fresh warm medium was added. Yellow-green fluorescent 
microspheres (FluoSpheres®, F8823, Invitrogen, now ThermoFisher Scientific) 
suspended in respective cell medium at 1 µl per 100 µl medium per well were 
added and gently mixed. 100 µl of cell medium without fluorescent 
microspheres was added per well to the negative controls. After one-hour 
incubation at 37°C in dark conditions, 1 ml of cold PBS was added to each well. 
The cell layers were washed with PBS, and were used for microscopy or 
harvested for flow cytometry analysis. For flow cytometry, cell layers were 
incubated in trypsin for 10 minutes. The trypsin was then neutralized and the 
cells resuspended in 1% paraformaldehyde for flow cytometry analysis on a 
Cyan ADP flow cytometer (Beckman Coulter). Cells with fluorescent intensity 
greater than 97% of the control cells were considered as positive.  
Matrigel assay 
Matrigel (BD MatrigelTM Basement Membrane Matrix, 354234, BD 
Biosciences, Bedford, USA) was thawed overnight at 4°C and then used to coat 
pre-chilled 48-well plates at 150 µl per well. The coated plates were allowed to 
settle overnight at 4°C, before being transferred to 37°C for at least one hour to 
solidify. Cells were harvested, labelled with Fluorescent Cell Linker Kit for 
General Cell Membrane Labelling (PKH67/PKH26, Sigma-Aldrich, St. Louis, 
MO, USA) following the manufacturer’s instructions. The cells were seeded on 
the Matrigel coated plates in 250 µl of EGM medium. HUVECs were seeded at 
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30,000 cells per well, and other cell types were seeded at different ratios with 
respect to HUVECs. The formation of capillary-like tubes was imaged using an 
Olympus IX71 inverted microscope and an Olympus CP70 microscope camera 
at 8, 16, and 24 hours. Images compromised by the presence of debris were 
excluded by an observer blinded to the experimental design. The cumulative 
network lengths in the rest of the images were quantified automatically with 
ImageJ (Rasband, 1997-2016) using the Angiogenesis Analyzer plugin 
(Carpentier, Martinelli, Courty, & Cascone, 2012).  
Spheroid sprouting assay 
ECs were seeded in round-bottomed non-adherent 96-well plate at 500 cells per 
well in endothelial cell growth medium supplemented with methylcellulose 
(1:2,000 v/v). The cells were allowed to form spheroids overnight. The next day, 
the EC spheroids were carefully harvested, washed once, and mixed with 
neutralized collagen I solution to a final collagen concentration of 0.8 mg/ml 
and a total volume of 1.5 ml per well. Where specified, PBMC-derived cells 
with or without exposure to MMC were added together with the endothelial 
spheroids into the collagen I solution. The mixture was added to 12-well plate, 
and was allowed to solidify for two hours in a humidified incubator at 37°C in 
an atmosphere of 5% CO2. 700 µl of endothelial cell growth medium was then 
added per well on top of the collagen I gel, and the spheroids sprouting was 
monitored for three days. Phase-contrast pictures were taken and the total sprout 
length was measured using ImageJ software (Rasband, 1997-2016).  
Time-lapse video of spheroid sprouting was taken at Nikon Imaging Centre, 
Singapore Bioimaging Consortium. At 24 hours after seeding, the spheroids 
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were transferred to an on-stage incubator and mounted on a Nikon N-STROM 
microscope equipped with a Cool Snap2 Camera and a motorized stage. For 
each spheroid, a phase contrast image and a FITC channel image were taken 
every 5 minutes over 2 days. The overlaid images were compiled into a time-
lapse video for each spheroid.  
Statistical analysis 
Statistical analysis was performed using R version 3.3.0 (R Core Team, 2016). 
Data were reported as mean±standard deviation (sd) or mean±standard error 
(se). An unpaired t-test was used to compare the mean number of harvested cells, 
adherent cells, and Ki67-positive cells. Two way ANOVA (with Tukey’s post 
hoc test) (Fox & Weisberg, 2011; Hothorn, Bretz, & Westfall, 2008) was used 
to compare mean cell length, phagocytosis levels, and mean cumulative network 
length in the matrigel network formation assay. One way ANOVA (with 
Tukey’s post hoc test) was used to compare mean spheroid sprout length in the 
spheroid assay.  
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List of antibodies used 
Table 2. List of antibodies used in Chapter 1 



























Tie2 C-20 SC-324 Rabbit 
polyclonal 























 A11072 Goat 
polyclonal 
1:400 Invitrogen 
PECAM-1: platelet endothelial cell adhesion molecule. VEGFR1: vascular endothelial growth 
factor receptor 1. vWF: von Willebrand Factor. DAPI: 4',6-diamidino-2-phenylindole.  
Results 
MMC treatment increased cell yield at day 5 
In our experience, we have routinely observed that a much higher number of 
cells can be generated from PBMCs when MMC is used during the first day of 
culture. We cultured PBMCs with (+MMC) or without (-MMC) the use of 
MMC, and harvested the generated cells at day 5 after seeding. Based on our 
previous flow cytometry study, the majority of these harvested cells were 
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BDACs based on CD206 expression (Blocki, Wang et al., 2015). When we 
evaluated the total cell numbers using a hemocytometer, in all 18 independent 
samples, the cell numbers from +MMC conditions were always higher than that 
from -MMC conditions. We were able to harvest a significantly greater number 
of cells from +MMC conditions (143±48x103 cells/million PBMCs) than from 
-MMC conditions (50±32x103 cells/million PBMCs) (mean±sd, unpaired t test, 
degrees of freedom (df) = 33, p = 1.2x10-6). For 12 of these samples, we 
recorded the number of PBMCs isolated per ml of blood. Similarly, from each 
ml of blood, we could generate almost three times more cells from +MMC 
condition (234±95x103) compared to from -MMC condition (84±43x103) (df = 
22, p = 0.00015) (Figure 2). 
 
Figure 2. Significantly higher number of cells can be harvested when PBMCs are exposed 
to MMC during the first day of culture. PBMCs were seeded according to the BDAC 
generation protocol with (+MMC) or without (-MMC) macromolecular crowding during the 
first day of culture. Cells were harvested and counted 5 days after seeding. Central line indicates 
the median. Whiskers indicate maximums and minimums. Left: Numbers of cells (x1000) 
generated per 1 million of PBMCs. Data from 18 different samples. Unpaired t-test, df=33, p = 
1.2x10-6. Right: Numbers of cells (x1000) generated per 1 ml of blood. Data from 12 
independent samples. Unpaired t-test, df=22, p = 0.00015. 




Figure 3. MMC increases yield of cells. PBMCs were seeded according to the BDAC 
generation protocol with (+MMC) or without (-MMC) macromolecular crowding during the 
first day of culture. At specified time points, cells were washed three times with HBSS, fixed 
with methanol, and stained with DAPI. Cells with positive nuclear DAPI staining were counted 
as adherent cells. Top: Representative bright field images taken 1 day and 5 days after seeding. 
Bottom: Quantification of number of adherent cells (mean±sd) per well at 6 hours, 1 days, 3 
days and 5 days after seeding. **: p<0.01. ***: p<0.001.****: p<0.0001. Student’s t Test 
(unpaired, df = 4, sample size = 3). Data published in Blocki, Wang et al. (2015). 
To obtain a better idea of the effect of MMC over time, we performed cell 
counting at different time points. PBMCs were seeded on fibronectin-coated 
culture plates either with (+MMC) or without (-MMC) the addition of 
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macromolecular crowders. At specified time points, the cell layers were washed 
and stained with DAPI for automated cell counting. At as early as 24 hours after 
seeding, the addition of MMC in the culture medium (+MMC) resulted in a 
significantly higher number of adherent cells compared to the -MMC condition. 
At day 5, the +MMC condition had more than double the number of cells 
compared to the –MMC condition (Figure 3).   
MMC treatment did not alter the percentage of proliferating cells 
 
Figure 4. Low percentage of Ki67-positive cells in both -MMC and +MMC conditions. Top: 
PBMCs were seeded according to the BDAC generation protocol with (+MMC) or without (-
MMC) macromolecular crowding during the first day of culture, and were fixed for 
immunocytochemistry staining at day 5. HUVECs (top left) were used as a positive control for 
Ki67 staining. Red: Ki67. Blue: Nuclear DAPI counterstain. Magenta: Co-localization of Ki67 
with DAPI staining. Representative images are shown from at least three independent blood 
samples. Bottom: quantification of the percentage of Ki67-positive cells. Mean percentages are 
shown. Error bar represents standard deviation.  
One possible reason for an increased cell number under +MMC condition could 
be an increased percentage of proliferating cells. To verify that, we compared 
the percentage of cells with positive Ki67 staining at day 5 (Figure 4). Ki67 is 
present in all cells in active phases of the cell cycle (reviewed by Scholzen & 
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Gerdes, 2000). Most of the HUVECs (positive control) showed positive staining 
for Ki67 in the nucleus region. However, the majority of cells in both -MMC 
and +MMC conditions (identified by DAPI nuclear counterstaining) did not 
express Ki67. The percentage of Ki67-positive cells in -MMC condition 
(0.9±0.4%) was not significantly different from that in +MMC condition 
(1.4±0.6%) (unpaired t test, p>0.05). In both +MMC and -MMC conditions, 
most of the Ki67-positive cells were found at the centre of colony-like clusters.  
MMC treatment resulted in a more elongated cell morphology. 
Besides the difference in cell number, we also observed that the majority of cells 
generated under +MMC condition had an elongated, spindle-shaped 
morphology, which was less often observed in cells generated under -MMC 
condition (Figure 5). In order to quantitatively compare the cell morphology, 
we measured the average cell length along the long axis using the ImageJ 
software (Rasband, 1997-2016). Consistent with our observation, we found that 
the +MMC condition generated cells about 50% longer compared to the –MMC 
condition (65±34 µm and 44±27 µm, respectively). Despite the cell-to-cell 
variation, the difference was statistically significant (two way ANOVA, F1,684 = 
99.2, p = 2.2x10-16). 
 




Figure 5. Cells generated using MMC have a more elongated morphology. PBMCs were 
seeded according to the BDAC generation protocol with (+MMC) or without (-MMC) 
macromolecular crowding during the first day of culture. Top: Representative bright field 
images of cells at day 5. Scale bar represents 100 µm. Bottom: Quantification of cell length 
along the long axis at day 5 (mean±se). 20 cells per condition per blood sample from 18 different 
blood samples were analyzed. ****: Two way ANOVA, F1,684 = 99.2, p = 2.2x10-16. 
MMC treatment increased the expression of angiogenesis-related and 
macrophage markers  
While the cell morphology gave an indication that there may be significant 
differences between the cells generated with or without MMC, we looked 
further into their marker expression using immunocytochemistry (ICC). We 
have previously demonstrated that BDACs express pericyte markers NG2 and 
PDGFRβ, as well as angiogenesis-related/endothelial cell markers VEGFR1, 
Tie2, and CD31 (Blocki, Wang et al., 2015). BDACs also expressed 
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macrophage marker PM-2K (Takeya, Tsuchiya, Shimokawa, & Takahashi, 
1991). We therefore compared the expression of these markers. Placenta 
pericytes (Pl-Prc) were used as positive control for NG2 and PDGFRβ, and 
negative control for VEGFR1, CD31, and Tie2, while HUVECs were used as 
negative control for NG2 and PDGFRβ and positive control for VEGFR1, CD31, 
and Tie2. The expression of NG2 in Pl-Prc displayed batch-to-batch variation 
(data not shown). Interestingly, the cells generated under +MMC condition had 
a stronger expression of the pericyte- and angiogenesis- related markers 
compared to the -MMC condition. The majority of -MMC cells also failed to 
show PM-2K expression, except for a few elongated cells (Figure 6). The data 
were not conclusive for CD31, as batch-to-batch variation was observed in 
+MMC conditions.  




Figure 6. MMC is necessary for the expression of angiogenesis-related and macrophage 
markers. Immunocytochemistry for pericyte, endothelial cell, and macrophage markers. Cells 
were generated from human peripheral blood mononuclear cells (PBMCs) with (+MMC) or 
without (-MMC) macromolecular crowding during the first day of culture. Human placenta 
pericytes (Pl-Prc) and human umbilical vein endothelial cells (HUVECs) were used as controls. 
Cells were fixed with methanol and stained with respective antibodies. Nuclei were counter-
stained with DAPI. Data published in Blocki, Wang et al. (2015). 
MMC treatment did not alter the phagocytic activity   
Next, we looked into if there were any functional differences between cells 
generated under -MMC and +MMC conditions. Phagocytosis is a common trait 
of macrophages, especially M2 macrophages. Cells were incubated in medium 
containing fluorescent latex beads of 1 µm diameter for one hour. Human 
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PBMC-derived macrophages were used as positive control. Most of the 
macrophages phagocytosed fluorescent spheres, and some were observed to 
have a high number of microspheres in the intracellular space (Figure 7A). 
HUVECs, the negative control, did not seem to take up microspheres, although 
some fluorescence could be seen in between the cells. A few microspheres were 
observed inside some cells generated under -MMC and +MMC conditions 
(white arrows), but both the number of spheres per cell and the percentage of 
cells that internalized microspheres were much lower than that in macrophages 
(positive control).  
Representative flow cytometry analysis shows that 47% (sd: 1%) of the 
macrophages phagocytosed microspheres, while the percentages of cells 
demonstrating phagocytic activity were low for HUVECs and cells generated 
under -MMC and +MMC conditions (7±1%, 8±2%, and 5±0%, respectively) 
(Figure 7B). We obtained consistent results from different donors, with 
macrophages having a significantly higher phagocytic activity than the other 
cell types. Both -MMC and +MMC cells showed similar phagocytic activity as 
the negative control, HUVECs (Figure 7C).  




Figure 7. Cells generated under -MMC and +MMC conditions do not phagocytose. Cells 
were incubated in their respective medium containing yellow-green fluorescent microspheres 
for 1 hour at 37°C. After that, the cell layer was washed with cold PBS, and used for microscope 
imaging or harvested for flow cytometry analysis. A: Phase contrast-FITC overlay image. Top: 
Cells incubated with fluorescent microspheres. Bottom: Control wells incubated in culture 
medium without any microspheres. White arrow: Cells with several microspheres in the 
intracellular space. B: Percentage of cells with positive fluorescent signal measured by flow 
cytometry. Results are represented as mean±sd. C: Percentage of cells with positive fluorescent 
signal measured by flow cytometry, samples were from three different donors. Sample size=3. 
Results are represented as mean±sd. ****: Cell type with significantly different phagocytosis 
level from the rest. Two way ANOVA with Tukey’s post hoc test, F3,24 = 992, p = 2.2x10-16. 
Some data published in Blocki, Wang et al. (2015). 
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MMC treatment did not change endothelial cell network stability on matrigel  
A matrigel-based network formation assay was used to compare the pro-
angiogenic capacity of -MMC and +MMC cells. When ECs were seeded on 
solidified matrigel, they spontaneously formed tubular networks, resembling 
capillary networks (Figure 8B). These networks gradually disintegrate with time. 
At 24 hours after seeding, the total cumulative network length is only about half 
of that at 8 hours.  When -MMC or +MMC cells were seeded together with ECs 
on matrigel, the initial network formation, measured by cumulative network 
length at 8 hours after seeding, was not significantly different from that in EC 
alone conditions (two way ANOVA, F2,122  = 0.15, p = 0.86). At 16 hours after 
seeding, both the -MMC and +MMC conditions had a higher mean cumulative 
network length than the EC alone condition (42.5±2.1mm, 39.8±1.8mm, and 
34.4±1.6mm, respectively). However, this difference was not significant (two 
way ANOVA, F2,140 = 1.85, p = 0.16). At 24 hours after seeding, both the -MMC 
and +MMC conditions preserved more networks than the EC alone condition, 
with mean cumulative network lengths of 34.4±2.1mm, 32.1±1.8mm, and 
25.4±1.6mm, respectively.  The addition of either -MMC or +MMC cells 
resulted in about 25% more preserved networks compared to the EC alone 
condition, and the difference was statistically significant (two way ANOVA, 
F2,145 = 6.74, p = 0.0016). MMC treatment did not affect the ability of the cells 
to stabilize EC networks, as there was no significant difference between the -
MMC and +MMC conditions at 24 hours (Tukey’s post hoc test, p>0.05) 
(Figure 8A).  




Figure 8. Both cells generated under -MMC and +MMC conditions stabilize EC network 
on matrigel. Endothelial cells (ECs) were seeded on matrigel coated 48-well plates at 30,000 
cells/well. When specified, PBMC-derived cells generated with (+MMC) or without (-MMC) 
the use of MMC were added at 15,000 cells/well. Phase contrast images were taken at 8, 16, 
and 24 hours after seeding and the cumulative network length per field of view was quantified 
with ImageJ (Rasband, 1997-2016). Data are from 16-18 different experiments. A: Mean 
accumulative network length. Error bars represent standard errors. *: Group with mean length 
significantly different from EC alone control (Tukey’s post hoc test, p<0.05). p-values were 
calculated using two way ANOVA. B: Representative phase contrast images.  
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MMC-treated cells showed increased capacity to promote endothelial cell 
spheroid sprouting in collagen I gel.   
The pro-angiogenic capacity of the -MMC and +MMC cells were compared 
using a second in vitro assay, an endothelial cell spheroid sprouting assay. EC-
formed spheroids were mixed with collagen I gel with or without the addition 
of -MMC or +MMC cells. EC spheroids formed sprouts into the collagen I gel. 
At the end of 3 days, the cumulative sprout length for each EC spheroid was 
measured, and we compared the average cumulative sprout length of the three 
conditions. Two way ANOVA analysis shows that both -MMC and +MMC 
conditions had mean cumulative sprout length significantly greater than that in 
EC alone control (F2,399 = 32.2, p = 9.7x10
-14), although over all, there was no 
significant difference between the -MMC and +MMC conditions (Turkey’s post 
hoc test). 
In 5 of the 8 experiments, +MMC cells induced sprouts of significantly greater 
average length than -MMC cells (Tukey’s post hoc test, p < 0.05) (Figure 9). In 
the other three experiments, both -MMC and +MMC cells induced more than 
1.5-fold increase of endothelial sprouting compared to EC-alone control, 
although there was no significant difference between the -MMC and +MMC 
groups (Tukey’s post hoc test, p>0.05).  
 




Figure 9. MMC-treated cells better promote endothelial cell spheroid sprouting. 
Endothelial cell (EC) spheroids (500 cells per spheroid, 11-23 spheroids per condition) were 
seeded in collagen I gel without any other cell types (control) or with 200,000 PBMC-derived 
cells generated with (+MMC) or without (-MMC) exposure to macromolecular crowding during 
the first day of culture (+MMC). The EC spheroids were allowed to form sprouts into the 
collagen gel for three days, and the accumulated length of sprouts were measured for each 
spheroid. Top: Phase contrast-FITC channel overlay image. Phase contrast: EC. FITC: -MMC 
or +MMC cells. Bottom left: Cumulative sprout length per spheroid. Results are shown as 
mean±se. ****: p<0.0001 (two way ANOVA, F2,399 = 32.2, p = 9.7x10-14). Line over bars 
indicates no significant differences between groups (Tukey’s post hoc test, p≥0.05). Bottom 
right: Fold change of cumulative sprouts length per spheroid normalized against control 
(mean±se). Results are from eight independent experiments. * over bar indicates significant 
difference between the -MMC and +MMC conditions (Tukey’s post hoc test, p<0.05).  
Discussion 
We have demonstrated that MMC is crucial not only for generating sufficient 
numbers of cells within 5 days, but also for producing cells with BDAC-specific 
characteristics and functions. The current results as well as previous literature 
suggest several possible ways in which the one-day MMC treatment could 
impact BDAC generation. 
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Before discussing the effect of MMC, we first need to find out the factors that 
are important for BDAC generation. I am going to argue that rather than the 
proliferation of adherent cells, Monocyte-BDAC differentiation and cell-matrix 
interaction play a crucial role. 
Looking at the number of adherent cells over time for +MMC condition (Figure 
3), the cell number at 24 hours more than doubled that at 6 hours, and it 
increased by another 4-fold within 2 days. If this was purely due to cell 
proliferation of the adherent cells, one would expect a high percentage of 
proliferating cells among the adherent population, similar to the level in a fast 
growing cell type such as HUVECs. However, from the Ki67 staining result 
(Figure 4), the percentage of proliferating cells in the adherent population was 
too low to account for the rapid cell number increase. At earlier time points, we 
did not manage to detect Ki67 signals in the adherent cells either (data not 
shown). Therefore, the increasing number of adherent cells most likely 
originates from the monocytes in the non-adherent population. The non-
adherent cells were removed during the washing steps, and therefore not 
accounted for in cell counting or staining. However, some of them remained 
loosely attached after the day 1 medium change, and may have contributed to 
the observed cell number increase in the subsequent days.  
Another observation is the importance of fibronectin coating in BDAC 
generation. Although FBS contains about 25 μg/ml of fibronectin (Hayman & 
Ruoslahti, 1979), or 2.5 μg/ml in the culture medium (containing 10% FBS), we 
found it necessary to coat the culture plates with 20 μg/ml of fibronectin 
overnight before the PBMC seeding. Reducing the fibronectin concentration to 
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2 μg/ml at the coating step resulted in a lower cell number and fewer elongated 
cells, similar to the effect of removing MMC (Figure S1, Annex A).  
The use of MMC during the first day of culture may influence BDAC generation 
through both aspects, by enhancing monocyte-BDAC differentiation and by 
modulating the extracellular matrix. After one day of MMC treatment, there 
were more than double the number of adherent cells in the +MMC condition 
than in the -MMC condition (Figure 3), giving the cells a head start for the next 
4 days of growth. We did not quantify and characterize the loosely attached 
population that was not removed at the day 1 medium change, therefore it is 
unclear if this population was also influenced by MMC treatment in terms of 
cell number and proliferation potential. A sub-population of CD14+ monocytes 
has been reported to proliferate in vitro (Clanchy, Holloway, Lari, Cameron, & 
Hamilton, 2006). However, there are no published reports yet on how MMC 
influences monocyte proliferation, although in our lab we have observed an 
increased proliferation in mesenchymal stem cells following MMC treatment 
due to an enhanced ECM deposition and its consequently improved cell-matrix 
reciprocity (Ang, 2015). On the other hand, Blocki, Wang et al. (2015) 
demonstrated that MMC enhanced differentiation of monocytes into M1 
macrophages by enhancing LPS signalling. It is possible that MMC either 
enhanced monocyte proliferation, or increased the percentage of monocytes that 
differentiated into BDACs.  
Besides monocytes (CD14+), the non-adherent population contains a 
heterogeneous mixture of lymphocytes, granulocytes, erythrocytes, and 
platelets. The importance of the interaction between monocytes (CD14+) and 
non-monocytes (CD14-) populations during the generation of fibrocytes has 
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been highlighted in Abe et al. (2001). They reported that CD14+ cells alone or 
with CD14- cells in the upper chamber of a transwell rarely differentiated into 
fibrocytes. Only when cell-cell contact was allowed between CD14+ and CD14- 
T cells, did fibrocytes emerge in culture. We observed similar results in BDAC 
generation as well (Figure S2, Annex A). BDACs were generated only with 
direct co-culture of CD14+ and CD14- cells. From our experience, the presence 
of platelets is another important factor in BDAC generation. PBMCs depleted 
of platelets did not yield as many BDACs. Therefore, a second possible 
mechanism of action for MMC may be that it enhances the interaction between 
monocytes and other cell populations, and thereby accelerates BDAC 
generation.  
Moreover, MMC may enhance BDAC generation through modulating the 
fibronectin matrix. MMC has been shown to increase extracellular matrix 
deposition as well as ECM remodelling (Chen et al., 2011; Ang et al., 2014). 
Fibronectin is one of the essential ECM components in wound healing. Together 
with fibrin, fibronectin comprises the provisional matrix during early stages of 
skin wounds (Clark et al., 1982). Besides providing structural support, 
fibronectin promotes migration of epithelial cells and fibroblasts, and activation 
of macrophages (reviewed by Lensekin, 2015). Plasma fibronectin coating 
supported fibroblasts attachment in a concentration-dependent manner (Corbett, 
Wilson, & Schwarzbauer, 1996). For migrating cells like fibroblasts, the fibres 
in the fibronectin coating guided their migration, increased cell spreading, and 
induced a spindle-shaped morphology (Hsieh & Chen, 1983). The MMC 
treatment may enhance fibronectin matrix deposition, and hence increases 
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monocyte attachment and subsequently their differentiation into spread-out, 
spindle-shaped BDACs.  
Obi et al. (2014) reported similar findings using dextran (100-200kDa) in EPC 
in vitro culture. They reported that incubation with 100mg/ml dextran increased 
the number of adherent cells from CD133+ peripheral blood monocytes by more 
than 3 times. No plausible mechanism was proposed to account for this increase. 
Finally, Blocki (2012) has shown that granulocytes and monocytes in the 
PBMCs take up both Ficoll 70 and Ficoll 400 macromolecules at a 
concentration of as low as 1µM. Rashid et al. (2014) and Zeiger et al. (2012) 
also reported Ficoll uptake by MSCs. MSCs seem to uptake Ficoll through 
pinocytosis into mitochondria, and then into lysosomes. Whether Ficoll uptake 
affects BDAC metabolism or activation remains unknown. Ficoll is also used 
in PBMC isolation from peripheral blood, so both -MMC and +MMC cells have 
several hours of contact with Ficoll before seeding. Therefore, Ficoll uptake 
may not be the main mechanism for enhancing BDAC differentiation. 
 
Conclusion 
The use of MMC during BDAC generation led to a higher cell yield, a more 
elongated cell morphology, stronger expression of angiogenic markers, and in 
most cases an increase in pro-angiogenic capacity in vitro. Therefore, this novel 
MMC protocol allows us to generate functional cells in relatively high numbers 
within 5 days, which is a substantial improvement over conventional protocols.  
After establishing the necessity for MMC, we used MMC in BDAC generation 









Chapter 2: BDACs rescued limb tissue in a 
murine hind limb ischemia model   
  




Previously, we demonstrated the pro-angiogenic potential of BDACs in vitro, 
and in a mouse tumour implantation model in vivo. In this thesis, we went on to 
further investigate the therapeutic potential of BDACs in a disease model for 
critical limb ischemia; namely, a murine hind limb ischemia (MHI) model. The 
MHI model is one of the most widely used pre-clinical animal models for 
investigating critical limb ischemia (Lee et al., 2004; Orbay, Hong, Zhang, & 
Cai, 2013). The principle of the murine hind limb ischemia model is to simulate 
the CLI condition by ligating the femoral artery or the external/common iliac 
artery, and thus to artificially create an ischemic region in the hind limb.  
We established the suitable ligation procedure using immunocompromised nude 
mice with BALB/c background. The location of ligation affects greatly the 
surgical outcome because of the presence of collateral circulation in the mouse 
hind limb (Goto et al., 2006). After comparing the surgical outcome of a more 
severe (ligation and cutting of the external iliac artery) with a less severe 
(ligation and cutting of the femoral artery) surgical approach, we decided to 
adopt the external iliac artery ligation, which provided us with sufficient 
therapeutic windows for BDAC treatment.  
We also optimized two methods for quantifying revascularization. Laser 
Doppler Imaging measures the distribution of superficial blood perfusion over 
a defined area of the skin. Laser Doppler Imaging generates signals non-
invasively using a low power He-Ne laser (Limbourg et al., 2009), and is able 
to measure the perfusion level typically up to a thickness of 0.5-1mm (Perimed). 
This technology has the advantage of being fast, non-invasive, and not too 
costly. The data are displayed in the form of a colour map indicating the two-
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dimensional distribution of perfusion level, with red indicating high perfusion 
level and blue low perfusion. It is necessary to normalize the perfusion data 
against the non-ligated foot to reduce variations between animals. Usually the 
mean perfusion is calculated and compared between animals at different time 
points (Niiyama, Huang, Rollins, & Cooke, 2009). 
Magnetic resonance angiography (MRA) is a protocol within magnetic 
resonance imaging (MRI). MRA makes use of a strong magnetic field, and radio 
frequency (non-ionizing) radiation, to generate contrast between flowing blood 
and stationary tissue. In contrary to Laser Doppler Imaging, which measures the 
surface blood perfusion, MRA is able to detect flow in major blood vessels and 
to reconstruct a 3D "map" of the blood vessel distribution (Korosec, 2009). An 
imaging protocol termed “time-of-flight” was used, in which moving objects 
such as blood appeared white, while the stationary tissue appeared black. After 
optimizing the MRA protocol, we were able to detect large blood vessels in the 
hind limb of the mice in vivo with no contrast agent. 
Two batches of animal experiments were planned. The first batch aimed to 
establish the efficacy of BDAC treatment, while the second aimed to look 
further into the mechanism. In the first batch of animal experiments, BDAC-
treated animals and vehicle (saline)-treated animals were followed up through 
visual observations and magnetic resonance angiography (MRA). Their 
recovery over time was recorded and used to establish the time points for the 
second batch of experiments. In the second batch of animal experiments, an 
additional monocyte treatment group was added. Animals would be sacrificed 
at weekly time points for histological analysis. Besides visual observations, 
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MRA and Laser Doppler Imaging would be used to access the perfusion 
recovery in the animal hind limbs.  
I designed the experiments. Dr Blocki, Dr Selina Poon, and I performed the 
animal surgeries and imaging, and I performed the histological work and data 
analysis. Dr Nikita Agarwal and Dr Sakthivel Sekar helped to set up and 
optimize the MRA protocol.  
Materials and methods 
Murine hind limb ischemia model 
All animal related procedures were in accordance with the Institutional Animal 
Care and Use Committee (IACUC) at Biological Resource Centre, A*STAR, 
Singapore. For the first batch of animal experiments (12th Mar.– 27th Apr. 
2014), male BALB/c nude mice (C.Cg/AnNTac-Foxn1nuNE9) were purchased 
from InVivos (Singapore), and were 10-19 weeks old at the time of surgery. For 
the second batch of animals (29th Aug. 2014 – 3rd Feb. 2015), due to supply 
shortage at InVivos, male BALB/c nude mice (BALB/cOlaHsd-Fox1nu) were 
purchased from Biological Resource Centre of A*STAR (Singapore), and were 
10 weeks old at the time of surgery. 
Anaesthesia was induced by injection of Ketamine (150 mg/kg) and Xylazine 
(10 mg/kg) at 0.06-0.09 ml/10g (BW). In some animals, the Ketamine/Xylazine 
dose had to be reduced to as low as 60% due to anaesthesia complications. The 
anaesthetic state of the animal was monitored during and after the surgical 
procedure through using the pinch-response and visible heart/breathing rate.   
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The mouse was placed in the supine position on a heated pad to maintain body 
temperature during surgery. Ophthalmic ointment was applied to protect the 
eyes from drying out. The right hind limb was sterilized using alternating iodine 
and alcohol swaps. An incision was made at the medial thigh towards the 
proximal thigh, and a retractor was placed to push the fat pad and other soft 
tissues proximally in order to expose the deep femoral artery and the epigastric 
artery branch. The external iliac artery was gently separated from the vein and 
the nerve bundle proximal to the deep femoral artery branch. The external iliac 
artery was ligated with two knots using 7/0 suture (Premilene, Braun, 
Melsungen AG), and was then cut in-between the two knots. Minimum or no 
bleeding was observed. The skin was closed with 5-0 or 6-0 suture. The animal 
was placed in a recovery cage and continuously monitored until it was awake. 
The unoperated left hind limb served as a control. The animals received 
subcutaneous injections of Enrofloxacin (10 mg/kg, once daily) for 5 days and 
of Buprenorphine (0.1 mg/kg, twice daily) for 3 days post-surgery. 
The operated mice were closely monitored for pain, distress, and trauma post-
surgery. The function and progression of necrosis in the operated hind limb were 
recorded. Following the IACUC requirement, animals with full foot necrosis 
within the first week were euthanized and excluded from the study. Animals 
with full foot necrosis after the first week were euthanized and the readout up 
to the point of euthanasia was used.  




For the second set of animal experiments, the operated hind limbs were 
evaluated using a functional scoring scale. 0: Dragging. 1: No plantar flextion. 
2: No toe flextion. 3: No grabbing force. 4: Some grabbing force. 5: Normal.  
Cell transplantation 
One day after surgery, the BDAC group was injected intramuscularly with 106 
BDACs (per animal) suspended in 0.1 ml of Hank's Balanced Salt Solution 
(HBSS). The cells were injected at three different sites on the operated hind 
limb, or about 0.33×106 cells per site. The monocyte group was injected with 
106 monocytes suspended in 0.1 ml HBSS, and the vehicle group was injected 
with HBSS only.  
Magnetic resonance angiography 
The vasculature of the animals was assessed using time-of-flight magnetic 
resonance angiography (MRA). For the first batch of animal experiments, MRA 
was performed with a 7T magnetic resonance imager (ClinScan, Bruker, 
Ettlingen, Germany) (flip angle = 70, FOV = 25X18.75 mm, TR = 20 msec, TE 
= 3.84 msec, slice number = 90, slice thickness = 0.3 mm, distance factor = -
2.00, spacing between slices = 0.294mm, average number = 6, acquisition time 
per animal = 43 minutes). The ligated hind limb and the tail were included in 
the angiography. For the second batch of animal experiments, MRA was 
performed with a 9.4T magnetic resonance imager (BioSpec, Bruker) (flip angle 
= 90, FOV = 25X25 mm, TR = 15 msec, TE = 3.32 msec, slice number = 150, 
slice thickness = 0.35 mm, spacing between slices = 0.15 mm, average number 
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= 1, acquisition time per animal = 7 minutes). Both hind limbs and the tail of 
the animal were included in the angiography. The mice were maintained under 
anaesthesia with isoflurane, and the body temperature maintained with a 
circulating water warmed-platform during the data acquisition. MRA was 
performed before the ligation surgery to obtain the baseline level of vasculature, 
as well as at various time points after the surgery (day1, week1, week2, week3 
and up to week4) to assess the recovery of perfusion in the hind limbs.   
MRA data was analyzed using ImageJ software (Rasband, 1997-2016). Blood 
vessels were segmented by manual thresholding. The total volume of blood 
vessels was calculated by multiplying the total vessel area per slice by the slice 
thickness. For the first batch of animal experiments, only slices 45 to 15 (from 
the start of thigh to lower calf) were used for vessel volume quantification. For 
the second batch of animal experiments, the branching point of the saphenous 
artery from femoral artery on the left hind limb (unoperated) was used as a 
reference, and the next 100 slices distal to the branching point were used for 
vessel volume quantification. For the second batch of animal experiments, the 
MRA data were first filtered using the ImageJ Tubeness plugin (Sato et al., 
1998), with a sigma value of 0.977.  
Laser Doppler Imaging 
During the second batch of animal experiments, Laser Doppler Imaging was 
performed with the mice under general anaesthesia using isoflurane. For the 
plantar foot imaging, the animals were placed in a prone position, and their hind 
limbs naturally extended, such that the plantar side of the feet faced upward. For 
the abductor thigh imaging, the animals were placed in a supine position, their 
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hind limbs naturally extended, and their thighs placed at the same distance from 
the Laser Doppler Imager sensor. At least three consecutive scans were taken to 
ensure that the readings were stable. Imaging was performed on day 0 (before 
surgery and after surgery), then on day 1 post-surgery (before the administration 
of cells or vehicle), and again on days 3, 7, 14, and 21 post-surgery.  
Laser Doppler Imaging data analysis was performed using PIMSoft software 
(Perimed AB, Stockholm, Sweden). Region of interest (ROI) was defined 
manually for the plantar paw and abductor thigh, and the average perfusion 
value per ROI was calculated. Only areas with signal intensity above a threshold 
of 0.3 were included in the average calculation, so that the background was 
excluded.  
Histology 
Mice were euthanized at pre-determined time points. The semimembranosus 
and semitendinosus muscles of the thigh as well as the gastrocnemius muscle 
of the calf were harvested. The muscles were fixed in 4% paraformaldehyde 
(4°C, 20 hours), paraffin embedded, and sectioned at a thickness of 5 µm for 
hematoxylin and eosin (H&E) staining. Alternatively, for the first batch of 
animal experiments, the muscles were kept in 4% paraformaldehyde for 2 hours 
at room temperature, and for the second batch of experiments, the muscles were 
soaked in 20% (w/v) sucrose solution at 4°C overnight. The muscles were then 
embedded in OCT compound, snap frozen, and cryosectioned at 10 µm (first 
batch of animal experiments) or 7 μm (second batch of animal experiments) for 
immunohistochemical staining. When necessary, antigen retrieval was 
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performed with 20 µg/ml proteinase K (P2308-5MG, Sigma-Aldrich, St. Louis, 
USA) for 7 minutes at 37°C prior to immunohistochemistry staining. 
For immunohistochemistry staining, the slides were blocked with 3% BSA in 
PBS for one hour, and then incubated in primary antibody solutions at 4°C for 
16 hours. The sections were washed three times with PBS and then incubated 
in secondary antibody solution with DAPI at room temperature for 30 minutes. 
After three washes in PBS, the slides were mounted in fluorescence mounting 
medium for microscopy. For quantification, 10x magnification microscopic 
pictures were taken with an Olympus IX71 inverted microscope and Olympus 
CP70 microscope camera, such that the whole muscle cross-section was 
covered. Positive staining area and nuclear count (DAPI, D1306, Invitrogen) 
density was calculated using ImageJ (Rasband, 1997-2016). Capillary or 
arteriole density was expressed as the area of positive CD31 or vWF staining 
over total muscle area, respectively. 
Statistical analysis 
Statistical analysis was performed in R version 3.3.0 (R Development Core 
Team, 2008). Boxplot and scatter plot diagrams were made using the plotly 
library (Sievert et al., 2016). Results are expressed as mean±sd. In the first batch 
of animal experiments, Mann-Whitney-Wilcoxon test was used to compare the 
mean semi-quantitative necrosis scoring and number of toes lost. An unpaired t 
test was used to compare mean total vessel volumes in MRA, and one way 
ANOVA was used to compare mean vessel areas in histological analysis. In the 
second batch of animal experiments, Kruskal-Wallis test (with Dunn post hoc 
test) was used to compare the mean necrosis and functional scoring. One way 
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ANOVA (with Tukey’s post hoc test) was used for analysis of data from Laser 
Doppler Imaging, MRA, and histological study.  
List of antibodies 
Table 3. List of antibodies used in Chapter 2 

























DAPI  D1306  1:1000 Invitrogen 
Alexa Fluor 488 
anti-mouse 
 A11029 Goat 
polyclonal 
1:400 Invitrogen 
Alexa Fluor 594 
anti-rabbit 
 A11072 Goat 
polyclonal 
1:400 Invitrogen 
Alexa Fluor 488 
anti-Rat 
 AB150 Donkey 
polyclonal 
1: 200 Abcam 
PECAM-1: platelet endothelial cell adhesion molecule. vWF: von Willebrand Factor. DAPI: 
4',6-diamidino-2-phenylindole.  
Results: Murine hind limb ischemia model batch one (12th Mar.– 
27th Apr. 2014) 
Animals and hind limb ischemia surgery 
A total of 16 animals were operated in the first batch of animal experiments. 
One animal did not recover from anaesthesia after the surgery, and another 
animal had to be euthanized due to progressive foot necrosis on day 3 post-
surgery, and were therefore excluded from the study. The rest of the 14 animals 
were randomly assigned to the vehicle group or the BDAC group. One BDAC-
treated animal was found dead on day 15 post surgery. It showed no necrosis 
and high revascularization from MRA studies, and no prior symptoms of 
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compromised health. The cause of death remains unknown, and this animal was 
excluded from the study. The success of the surgery was confirmed by pale palm 
colour as well as MRA analysis at day 1. No adverse reaction to BDAC 
treatment was observed.  
A single injection of BDACs resulted in significantly improved tissue 
preservation and functional recovery.  
The single-dose BDAC treatment significantly reduced tissue necrosis in the 
ligated hind limb compared to the vehicle-treated animals. Most vehicle-treated 
animals showed necrosis of one or more toes. One animal needed to be 
sacrificed prior to the end of the study due to progressive foot necrosis. In the 
BDAC-treated group, all animals except one were completely free of necrosis. 
The exception animal showed necrosis of one toe during the first week, but the 
necrosis did not progress any further during the study (Figure 10).  
We performed semi-quantification of the degree of necrosis in the BDAC and 
vehicle-treated animals following a scoring system (Figure 10). Consistent with 
our observation, the BDAC-treated animals had lower levels of necrosis 
compared to the vehicle-treated animals at all time points. Similar results were 
obtained by comparing the average number of toes affected (discoloration or 
necrosis of nail or toe) per animal. The vehicle-treated animals had an average 
of three toes affected per animal at week 4, while only one toe necrosis was 
observed in the BDAC-treated group.  
We were not able to compare the hind limb functions in terms of ambulation 
and grabbing force between the two groups, because most of the control animals 
had lost multiple digits. 




BDACs injection accelerated revascularization at early time points (week 1-
2).  
In order to investigate how BDACs improved the mice’s recovery in the hind 
limb ischemia model, we monitored the vascularization in the limb by time-of-
flight magnetic resonance angiography over a course of 4 weeks. For each set 
Figure 10. BDAC treatment reduces 
degree of necrosis. Top: Representative 
images of the hind limbs at the end of week 
2, with the magnified images of the right 
paw (ligated) on the right. Middle: The 
mean ischemia score of the vehicle-treated 
(control) and the BDAC-treated animals at 
different time points. A semi-quantitative 
scoring system for the degree of ischemia 
was used. Bottom: Average number of toes 
affected per animal at different time points. 
There were 7 animals in the vehicle group 
and 6 animals in the BDAC group. p-values 
were calculated using Mann-Whitney-
Wilcoxon Test. Data published in Blocki,
Wang et al. (2015). 
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of MRA data, we defined the region of interest (ROI) at the calf region of the 
right hind limb (the ligated one). The total volume of blood vessels was 
calculated within the ROI. The average total blood vessel volume was compared 
between the BDAC and vehicle-treated groups at different time points (Figure 
11).  
MRA analysis performed one day after surgery confirmed that there were no 
detectable blood vessels in the limb, confirming complete ligation of the 
external iliac artery (Figure 11). Revascularization was observed in both 
treatment groups, however at as early as week 1, the average vessel volume in 
the BDAC-treated group became higher than that in the vehicle group, although 
the difference was not statistically significant due to the outlier in the vehicle 
group (p = 0.33) (Figure 11). At week 2, the vessel volume exceeded that of the 
baseline only in the BDAC group. The lowest vessel volume in the BDAC group 
(6.4 μl) is higher than the highest vessel volume in the vehicle group (5.8 μl).  
However, this time point was not powered to detect statistical significance, as 
we were not able to perform MRA for all animals due to technical issues. At 
weeks 3 and 4, the ischemia appeared to be resolved in both experimental 
groups as the vessel volumes were comparable to that of the baseline (Figure 
11). The higher vessel volume in the BDAC-treated group at early time points 
indicates that BDACs helped to accelerate the revascularization process in the 
ligated hind limb. 




Figure 11. MRA analysis shows that the BDAC-treated animals had higher average total 
vessel volume at week 1 and week 2. Top: representative reconstructed MRA images showing 
the vessel structure of the tail (left) and the right hind limb (right), with the ROI indicated by 
the red boxes. Bottom: Quantification of vessel volume (in μl) in the ROI. Overlay of boxplot 
and scatter plot is shown. Each point represents an individual animal. The centreline of the 
boxplot represents the median. The lower and upper horizontal lines of the rectangle represent 
the 1st and the 3rd quartile, respectively. The lower and upper whiskers of the boxplot represent 
the minimum and the maximum data point. Points outside the boxplot represent outliers. 
Statistical analysis was performed using one way ANOVA. Data published in Blocki, Wang et 
al. (2015).  
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No significant difference in capillary density at week 4.   
 
Figure 12. No significant difference in vessel area measured by immunohistochemistry 
(IHC). Top: Representative IHC staining of the cryosections from the calf muscles harvested at 
week 4. Red: CD31. Green: von Willebrand factor. Bottom: Quantification of vessel area based 
on the IHC staining (mean±standard deviation). Data analysis was performed using one way 
ANOVA. Line over bars indicates no significant differences (p>0.05). Numbers below bars 
indicate sample sizes. Data published in Blocki, Wang et al. (2015). 
At the end of week 4, histological analysis was performed to evaluate the vessel 
density in the calf muscles. CD31 (PECAM-1) is an endothelial cell marker and 
labels all blood vessels, while von Willebrand Factor (vWF) labels larger blood 
vessels. As expected from the MRA result, there was no significant difference 
between the vessel densities in the vehicle and BDAC-treated group. Both the 
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vehicle and BDAC-treated animals had similar vessel densities in the ligated 
hind limb, which tended to be higher than the vessel densities in the non-ligated 
ones (Figure 12). 
Results: Murine hind limb ischemia model batch two (29th Aug. 
2014 – 3rd Feb. 2015) 
Animals and hind limb ischemia surgery 
Having demonstrated the efficacy of BDACs and their possible role in 
promoting revascularization, a second batch of animal studies was designed 
with several objectives in mind: Firstly, to include more animals per group to 
increase the statistical power. Secondly, to sacrifice animals at intermediate 
time points to capture early changes through histological analysis. Thirdly, to 
add a monocyte-treated group to investigate if BDACs have additional benefits 
compared to undifferentiated monocytes. The timing of the study was shortened 
to three weeks, since most changes occurred from week 1 to week 3 in the first 
batch of animal experiments.  
During the first batch of animal experiments, we observed that more animals of 
12 weeks old or younger experienced necrosis (5 out of 8 animals) compared to 
older animals (1 out of 5 animals) (data not shown). Therefore, we decided to 
use younger animals (10 weeks) during the second round of experiments to 
avoid age-related differences.    
As we were ordering the animals for the second set, there was an indefinite 
shortage of BALB/c nude mice supply with the original animal provider, 
InVivos. Therefore, we had to switch the animal supplier to Biological Resource 
Centre of A*STAR, Singapore.  
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A total of 40 animals were operated in the second batch of animal experiments. 
One animal did not recover from anaesthesia after the surgery. One animal had 
to be euthanized on day 1 and two on day 3 because of extensive paw necrosis. 
These four animals were therefore excluded from the study. The rest of 36 
animals were randomly assigned to the vehicle, monocyte, or BDAC-treated 
group. At the end of week 1, 2, and 3, three or four animals were randomly 
selected and sacrificed per group for histology study. The success of the surgery 
was confirmed by pale palm colour, Laser Doppler Imaging 6 hours post-
surgery, as well as MRA analysis at day 1 post-surgery. No adverse reactions to 
treatment were observed in any animal groups studied.  
Significantly less necrosis was observed in the second batch of animal 
experiments compared to the first set.  
Despite the same surgical procedure and animal aftercare, the second batch of 
animals showed much stronger intrinsic recovery, which is evident when 
comparing the vehicle-treated animals from the first and the second batch of the 
animal experiments (Figure 13). While in the first batch of animal experiments, 
most of the vehicle-treated animals showed varying degree of necrosis, only two 
out of twelve animals from the vehicle group showed any necrosis in the second 
batch. The severity of necrosis was also much lower in the second batch of 
animal experiments. One of the two animals had necrosis of three nails and the 
other one had a toe necrosis. In comparison, in the first batch of animal 
experiments, 4 animals out of 7 had more than two necrotic toes. The difference 
between the two batches of animal experiments was statistically significant both 
in terms of average ischemia score and average number of affected toes.   




Figure 13. The vehicle-treated animals from the second batch of animal experiments 
developed significantly less necrosis compared to the first batch. Left: Average ischemia 
score of vehicle-treated animals from the first batch of animal experiments (7 animals) or from 
the second batch of animal experiments (12 animals). For euthanized animals, the last score was 
used for all subsequent time points. Ischemia scores were determined according to the scoring 
system in Figure 10 and Figure 14. 0: No necrosis. 1: One nail discoloration. 2: ≥2 nails 
discoloration. 3: One toe discoloration. 4: ≥2 toes discoloration. 5: Foot necrosis, euthanized. 
Right: Average number of toes affected (nail or toe discoloration) per animal. Mann-Whitney-
Wilcoxon test was used for statistical analysis. 
Among the 36 animals included in the second batch of hind limb ischemia 
model, only one animal in the BDAC-treated group developed necrosis at the 
tip of middle digit, and one in vehicle-treated group developed half-toe necrosis 
(Figure 14. Bottom right). Moreover, one animal from each of the three groups 
showed one or multiple nails discoloration. There was no significant difference 
between the degree of necrosis across different treatment groups.  




Figure 14. Necrosis was rare and not severe in all three treatment groups in the second 
batch of animal experiments. Top: The mean ischemia score of the vehicle-treated, monocyte-
treated and the BDAC-treated animals from the second batch of animal experiments. A semi-
quantitative scoring system for the degree of ischemia was used. Bottom left: Average number 
of toes affected per animal at different time points. There were 12 animals per treatment group. 
For euthanized animals, the last score was used for all subsequent time points. Bottom right: 
Representative images of the paws from the operated limb (right hind limb) at the end of week 
3, as well as the paws with the most severe necrosis from each group. No statistical significance 
was found between any treatment groups.  
The BDAC-treated animals had accelerated functional recovery after 
ischemia 
Although we did not observe significant difference in terms of the degree of 
necrosis, we were able to compare the hind limb function of animals from 
different treatment groups. Interestingly, the BDAC-treated animals 
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demonstrated much earlier recovery of toe function compared to the other two 
treatment groups, especially to monocyte-treated group (Figure 15).  
 
The BDAC-treated group had the highest average function score among the 
three groups, and the difference at week 1 was statistically significant between 
the BDAC and monocyte-treated group, as well as the Vehicle and monocyte -
treated group (Kruskal-Wallis test with Dunn post hoc test, p = 0.0011). At week 
1, three out of twelve BDAC-treated animals were able to grab with toes of their 
operated limb, while none of the animals in other groups were able to do so. At 
week 2, four out of nine BDAC-treated animals were able to grab with toes of 
Figure 15. BDAC-treated animals 
demonstrated earlier functional 
recovery. Top: Average function score 
for each treatment group using a semi-
quantitative scoring system. p values 
were calculated with Kruskal-Wallis 
test. Bottom: The percentage of 
animals able to grab with toes of the 
operated hind limb (function score ≥4). 
At day 1 and week 1, there were 12 
animals per treatment group. At week 
2, there were 9 animals in the BDAC- 
or monocyte-treated group, and 8 
animals in vehicle-treated group. At 
week 3, there were 6 animals each in 
the BDAC- or monocyte-treated 
groups, and 4 animals in the vehicle-
treated group.  
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their operated limbs, while only one animal from the monocyte- or vehicle- 
group was able to do so. At week 3, however, the monocyte-treated animals 
caught up with their toe function recovery, with 5 out of 6 animals able to 
perform grabbing function, similar to the BDAC-treated group (4 out of 6). 
No significant difference between revascularization measured by magnetic 
resonance angiography   
We quantified the total blood vessel volume in the ROI in the mice hind limb 
using time-of-flight MRA, which captures areas of movement; in our case, the 
flowing blood. All treatment groups recovered to at least 60% of the baseline 
level within the first week, which was maintained throughout the duration of 
the experiment. The BDAC-treated animals tended to have slightly lower vessel 
volume ratio (operated/unoperated hind limb) compared to the vehicle and 
monocyte-treated group. The difference between the monocyte and BDAC-
treated group was statistically significant at week 2 (one way ANOVA, F2,33 = 
1.1, p = 0.03). At week 3, there was a trend that the BDAC-treated group had 
lower ratio of total vessel volume compared to the vehicle-treated group (one 
way ANOVA, F2,13 = 3.4, p = 0.06) (Figure 16).  




Figure 16. MRA analysis showed similar vessel volume ratio in all treatment groups. Time-
of-flight magnetic resonance angiography (MRA) was used to capture perfused blood vessels 
in vivo at different time points. Top: Representative 3D projections of MRA data. Bright area 
represents blood vessels. Bottom: The y-axis represents the ratio of total vessel volume in the 
ROI in the right hind limb (operated) and the left hind limb (unoperated). p-values were 
calculated by one way ANOVA with Tukey’s post hoc test. At day 1 and week 1, there were 12 
animals per treatment group. At week 2, there were 9 animals in the BDAC- or monocyte-
treated group, and 8 animals in vehicle-treated group. At week 3, there were 6 animals each in 
the BDAC- or monocyte-treated groups, and 4 animals in the vehicle-treated group. 
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All treatment groups had similar surface blood reperfusion as measured by 
Laser Doppler Imaging 
For this second batch of animal experiments, we were able to confirm the MRA 
analysis using Laser Doppler Imaging, which measures the surface blood 
perfusion in vivo. Two different areas were selected for Laser Doppler Imaging 
measurement: The plantar surface of the paws (with the mice in a prone position) 
and the abductor thigh region (with the mice in a supine position) (Figure 17).   
 
Figure 17. Determining the mean perfusion value by Laser Doppler Imaging. Both the 
plantar paws and the abductor thighs were analyzed for surface blood perfusion using Laser 
Doppler Imager. Left column: Camera view. Middle column: Signal intensity distribution map, 
which is used to determine the ROIs. Green area represents background with a perfusion value 
below the threshold value of 0.3, and was excluded from the mean perfusion calculation. Dark 
area represents low signal intensity while light areas represents high intensity. Right column: 
Perfusion measurement distribution map, where blue colour represents area with low surface 
blood perfusion measurements, and red represents area with high blood perfusion measurements. 
The mean perfusion value is calculated over each of the ROIs. Red arrow: The operated hind 
limb (right hind limb).  
The Laser Doppler Imaging data showed a similar trend as the MRA data, with 
a peak in perfusion values at the early time points, which returned towards the 
baseline at the later time points. For the plantar foot measurement, both vehicle 
and monocyte-treated group showed a sudden peak at week 2 and a decrease 
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from week 2 to week 3, while in the BDAC group the perfusion gradually 
increased from the post-surgery time point to week 3. The vehicle-treated group 
had a significantly higher mean perfusion ratio in the plantar paws than the 
BDAC-treated group at week 2 (one way ANOVA, F2,23 = 3.5, p = 0.048, with 
Tukey’s post hoc test). There was also significant difference between the 
vehicle and monocyte-treated group at the pre-surgery time point (F2,35 = 3.6, p 
= 0.037) (Figure 18). 
In the abductor thigh region, the mean perfusion ratios in all three treatment 
groups seem to follow the same trend, with a peak at week 1. No statistically 
significant differences were observed between the groups at all time points 
(Figure 18).  




Figure 18. Laser Doppler Imaging measurement showed similar ratios of mean surface 
blood perfusion in all treatment groups. Surface blood perfusion in the hind limbs was 
monitored with Laser Doppler Imaging. Y-axis represents ratio of mean perfusion in the 
operated limb over that in unoperated limb. p-values were calculated by one way ANOVA with 
Tukey’s post hoc test. At day 1 and week 1, there were 12 animals per treatment group. At week 
2, there were 9 animals in the BDAC- or monocyte-treated group, and 8 animals in the vehicle-
treated group. At week 3, there were 6 animals each in the BDAC- or monocyte-treated groups, 
and 4 animals in the vehicle-treated group. 
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The BDAC-treated animals had lower capillary density compared to 
monocyte- or vehicle-treated animals 
Using immunohistochemistry, we quantified the area of CD31-positive staining, 
an endothelial cell marker, in the gastrocnemius muscle cross-sections. The 
largest difference was observed in muscles harvested at week 3 post-surgery. 
The BDAC-treated group had significantly less CD31+ area compared to the 
vehicle- treated groups (Tukey’s post hoc test, p<0.05). Unexpectedly, the 
vehicle-treated group has the largest CD31+ area among all treatment groups 
(Figure 19).  
 
Figure 19. The vehicle-treated group had the largest CD31-positive area in the 
gastrocnemius muscle cross-section. Mice were sacrificed at the end of week 1, 2, and 3. The 
gastrocnemius muscles were harvested, embedded in OCT compound, and snap-frozen. One 
transverse cryosection of 7 µm from each animal was stained with anti-CD31 antibody. 
Wholemount images were taken at 10x using an Olympus microscope. The total CD31 positive 
area for each cross-section was quantified automatically ImageJ software (Rasband, 1997-2016). 
Values are averages of at least three animals (±sd). p-values were calculated by one way 
ANOVA (with Tukey’s post hoc test).  




Interestingly, we repeatedly observed in both batches of animal experiments a 
peak in vascularization at early time points (week 1 or week 2), which gradually 
decreased with time. For example, in the first batch of animal experiments, we 
observed a maximum total vessel volume in the BDAC-treated animals at week 
2 (Figure 11). Similarly, in the second batch of animal experiments, we 
observed the same trends in MRA and Laser Doppler Imaging results (Figure 
16 and 18). At first glance, the first increase and then regression of blood 
perfusion seems contradictory, since we expected progressive increase of blood 
flow in response to the ischemic condition. However, vessel regression is also 
an integral part of angiogenesis, which is sometimes overlooked (reviewed by 
Wietecha, Cerny & DiPietro, 2012). Blood vessels are often produced in excess 
in wound healing, which are then remodelled to form the mature vessel network. 
In the first batch of animal experiments, BDAC treatment resulted in 
preservation of limb tissue and function, while most vehicle-treated animals lost 
multiple digits or even the whole foot. This is a strong piece of evidence for 
BDACs’ therapeutic potential. The reduction in tissue necrosis correlated with 
an accelerated revascularization. Increased angiogenesis or arteriogenesis likely 
contributed to BDACs’ therapeutic effect.  
In the second batch of animal experiments, we did not observe such significant 
vascular differences between the treatment groups. The difference in the two 
batches of animal experiments was unexpected. The improvement in the 
BDAC-treated animals compared to control animals was much more 
pronounced in the first round. However, closer scrutiny revealed that the main 
difference between the two batches of experiments was the recovery rates of the 
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control animals. The control animals in the second batch of experiments 
recovered much faster and more completely compared to in the first batch of 
experiments. While they received only saline injection, the control animals 
intrinsically recovered 60% of blood perfusion within the first week (Figure 16).  
We first suspected that the difference was due to different surgical skills during 
the two batches of animal experiments. The first set of surgeries were performed 
by Dr Anna Blocki and myself, while the second set of surgeries were 
performed by Dr Selina Poon and myself. Dr Blocki had more experience in 
animal surgery, while Dr Poon and I learned from scratch and took slightly 
longer time per surgery. However, we did not identify any factors that may have 
contributed to the different outcomes. Moreover, during the second batch of 
animal experiments, we performed the same surgical procedure for a batch of 
C57BL/6N animals in an independent study (unpublished data). C57BL/6 has 
been reported to have a much faster recovery rate and lower tissue necrosis 
compared to the BALB/c mice. Surprisingly, we did not observe any significant 
difference in the recovery rate and tissue necrosis between the control groups of 
C57BL/6N and BALB/c nude mice. That means the BALB/c nude mice in the 
second batch of experiments had an intrinsic recovery capacity comparable to 
the C57BL/6N mice.  
It then became apparent to us that there were biological differences between the 
two batches of BALB/c nude mice we used. For the first batch of animal 
experiments, we ordered our animals from InVivos (Singapore). However, 
when we were planning the second batch of animal experiments, we had to 
change the animal provider to Biological Resource Centre of A*STAR 
(Singapore) because of a supply shortage. After inquiring with the two animal 
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providers, I realized that although both batches of animals were of the BALB/c 
nude strain, they had different substrain background. The substrain background 
was not indicated by the animal providers upon animal ordering.  
Unfortunately, since the second batch of experiments was designed as a 
progression rather than comparison of the first, many readout parameters were 
modified, rendering the results not comparable between experimental batches. 
The first batch of animals were sacrificed at four weeks post-surgery, while the 
second batch of animals were sacrificed at the end of week one, two, and three. 
A higher field magnetic resonance imaging system was used for the second 
batch of animal experiments. Lastly, Laser Doppler Imaging was performed 
only for the second batch of animal experiments. Nevertheless, this incident 
prompted me to examine more carefully the different BALB/c nude substrains 
in the murine hind limb ischemia model, an area rarely covered in the literature. 
The next chapter will be devoted to the background and implications of these 
findings.  
Although we did not observe any difference in revascularization between the 
different treatment groups in the second batch of animal experiments, BDAC 
treatment did result in faster functional recovery. Therefore, besides promoting 
angiogenesis, BDACs may have other functions in an ischemic environment. 
The preliminary results will be described in Chapter 4.  
  




BDACs demonstrated strong therapeutic potential by preventing limb necrosis 
in the first batch of animals. The effect may be attributed to an accelerated 
revascularization. Despite the vastly different intrinsic recovery of the two 
batches of animals, an improvement in functional recovery in the BDAC-treated 
animals could still be observed in the second batch of animals. Therefore, these 
two batches of animal experiments supported the potential therapeutic value of 










Chapter 3: The impact of substrains on 
surgically induced hind limb ischemia (a 
literature review) 
  




This chapter describes retrospective considerations on the importance of 
substrain selection in ischemic models.  
As described in Chapter 2, we conducted two batches of experiments of the 
murine hind limb ischemia model using BALB/c nude mice. The second batch 
of animals had a surprisingly fast speed of revascularization and recovery after 
ligation of the external iliac artery. After closely examining the experimental 
setups and procedures, we concluded that there was no difference in animal 
treatment, surgical procedure, and post-surgery follow-up. The only significant 
difference was the change of animal provider from InVivos (Singapore) to 
Biological Resource Centre of A*STAR (Singapore). Although both batches of 
mice are of the same strain (BALB/c nude), and are both inbred stock, they are 
derived from different substrains. Therefore, they may harbour significant 
genetic differences, which led to different experimental outcomes.    
It has long been noted that different strains of mice respond differently in the 
murine hind limb ischemia model. For example, C57BL/6 mice are known to 
show a faster recovery than BALB/c mice. However, there are no reports on the 
different BALB/c nude substrain susceptibility in the murine hind limb ischemia 
model. Many publications today do not provide information on the exact mouse 
substrain used. It appears that authors are often not aware of the existence of 
such a substrain, nor might the distributors. The lack of knowledge on mouse 
substrains is probably one factor that contributes to the difficulty in reproducing 
animal experiment data between different laboratories. More information on a 
specific substrain’s performance in murine hind limb ischemia model would 
provide valuable information for selecting the suitable animal supplier. This 
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prompted me to examine the literature on the effect of genetic background on 
the murine hind limb ischemia model, especially at the substrain level. The 
observations are presented in this chapter.  
Substrains of BALB/c and BALB/c nude mice 
Among experimental mouse strains, BALB/c is one of the most commonly used 
in animal experimentation. Potter (1985) gave the most comprehensive account 
of the history of BALB/c up to the 1980s. The BALB/c strain dates back to 1913, 
when Halsey Bagg (Memorial Hospital, New York City, US) started to breed 
and maintain a stock of albino mice. These albino mice are named “Bagg albino” 
or BALB. This stock of mice gave rise to many mouse strains used today, 
including C3H, CBA, and BALB/c. The name BALB/c was coined by George 
Snell, when he brought these mice into Jackson Laboratory in 1932. Another 
closely related subline, BALB/wm, was derived by J. T. Syverton in 1950 (Cold 
Spring Harbor) and maintained at Ann Arbor.  
The Snell line split into three main branches (Figure 20). The branch derived by 
H. B. Andervont is the progenitor of numerous substrains, including BALB/cBy, 
BALB/cAnN, BALB/cHeA, BALB/cAnPt, BALB/cSKI, and BALB/cArg. Of 
these, the NIH substrains BALB/cBy and BALB/cAnN (later acquired by 
Tarconic) are probably most widely used. The second branch from the Snell 
BALB/c was derived by Earl Green, which later became substrains BALB/cWt 
and BALB/cORNL. The third branch was derived by J. P. Scott, which later 
became the BALB/cJ substrain and its derivatives.  




Figure 20. The BALB/c family of sublines containing 4 major branches: Andervont, Scott, 
Green and Murphy. The BALB/c Mouse. Edited by Potter & Michael (1985)/Current topics 
in Microbiology and immunology, volume 122, 1985, page 5, Potter. With permission of 
Springer.  
Today, more than a century has passed since Bagg first established the albino 
mice colony that became the BALB/c mice. However, besides Potter’s account, 
literature on the development of BALB/c strain has been scarce, and that on 
BALB/c nude mice almost non-existent. Meanwhile, the BALB/c mice 
substrains have evolved significantly since Potter’s 1985 publication. Some of 
the original BALB/c substrains, such as BALB/cAnπ, BALB/cHeA, 
BALB/cSKI, BALB/cArg, BALB/cWt, BALB/cORNL, and BALB/cWM are 
no longer widely used or commercially available. On the other hand, new 
BALB/c substrain has been developed due to the expanding number of animal 
breeding and distribution facilities worldwide. National Institutes of Health 
(NIH), US, Jackson Laboratory, and Charles River Laboratories remain 
important sources for BALB/c mice, especially in the US and Europe. At the 
same time, a number of companies have started to provide alternative sources 
of laboratory animals in Asia and Australia, such as CLEA, SLC and KBT 
Orient in Japan, NARA Biotech in Korea, and Animal Resources Centre (ARC) 
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in Australia. Many research institutes also have their own animal holding and 
breeding units, further increasing the variability in the animals’ genotypes and 
phenotypes.  
According to the guideline from the International Committee on Standardized 
Genetic Nomenclature for Mice (2016), a stock of mice can be called a substrain 
after 20 generations of inbreeding, which takes around 10 years or less. In this 
case, there are probably as many substrains as the number of institutes that 
maintain inbred mice. The origin and development of each of these substrains 
should in theory be tracked by using the full substrain name that includes the 
laboratory code of all institutes that have maintained the specific stock of mice 
in history. This is not always put into practise.  
As a result, during the animal procurement process, the substrain of the BALB/c 
mice is often not stated or overlooked by institute animal facilities and local 
distributors. Regardless of the source of the animals, they are usually simply 
referred to as BALB/c. The recognition of substrains is slightly better for some 
other animals, such as the C57BL6 mice. It is well known that the C57BL/6J 
and C57BL/6N substrains may perform differently in animal models, and it is 
usually specified which substrain was used in a study. However, the substrain 
differences in BALB/c are not generally recognized. While most organizations 
and institutes do have clear records of the source and development of their 
BALB/c mice, such information is often not directly available on the company 
or institute website.  
Through compiling the information available online and through inquiring 
directly with the animal providers, I assembled an updated history of the 
commonly used BALB/c and BALB/c nude mice substrains today (Figure 21 
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and Table 3). I did not include any outbred BALB/c mice, which have an 
undefined genetic background and are also used in some studies. The BALB/c 
mice commonly used today derive either from the Andervont branch (1937) or 
from the Scott branch (1938/9). The Andervont branch gave rise to the NIH 
BALB/c stock, which further developed into BALB/cBy and BALB/cAnN 
substrain. These mice and their derivatives are maintained and distributed by 
companies such as the Jackson Laboratory, Charles River Laboratories, 
Tarconic, and SLC. They are much more widely used than the Scott branch mice. 
The BALB/c nude mice used in my first batch of animal study are derived from 
the BALB/cAnN substrain from the Andervont branch.  
The Scott branch, on the other hand, gave rise to the BALB/cJ substrain and its 
close relatives. They are rarely used in the murine hind limb ischemia model. 
These mice are distributed by the Jackson Laboratory, Envigo (formally Harlan 
and OLAC), and the Animal Resources Centre of Western Australia. The 
BALB/c nude mice used in my second batch of animal study are derived from 
the BALB/cOlaHsd substrain from the Scott branch.  
One commonly used substrain, BALB/cA, is of unknown origin. It could be 
tracked back to 1956, when Cancer Research Institute (Aarhus, Denmark) 
received a batch of BALB/c mice from the Chester Beatty Institute (now the 
Institute of Cancer Research, London) (personal communication with CLEA, 
Japan). However, it is unclear from which substrain these mice were derived.  
 




Figure 21. A pedigree of common BALB/c and BALB/c nude mice substrains. Solid arrow: 
Inbred lineages. Dotted arrow: Congenic or unknown lineages. Shaded boxes: BALB/c nude 
mice substrains used in our first (C.Cg/AnNTac-Foxn1nuNE9) and second (BALB/cOlaHsd-
Fox1nu) batch of animal experiments. Italics: The year and the institute or investigator who first 
introduced or developed each of the substrain. ?: Unknown origin. ABU: Animal Breeding Unit, 
University Western Australia, AU. ARC: Animal Resources Centre, AU. CBI: Chester Beatty 
Centre, UK. CRI: Cancer Research Institute, Denmark. Crl: Charles River Laboratories. Jax: 
The Jackson Laboratory, US. LAC: Laboratory Animal Centre, UK. NIH: National Institutes of 
Health, US. NCI: Division of Cancer Treatment, National Cancer Institute, US. OLAC: OLAC 
(Harlan Laboratories, now Envigo), UK. SLC: Japan SLC, Inc, JP.  
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Table 4. Some commercially available BALB/c and BALB/c nude mice 
substrains. 
Branch BALB/c substrains Derived BALB/c 
nude substrains 
Distributor 



















BALB/cCrSlc  SLC, Japan 
 BALB/cSlc-nu/+ SLC, Japan 
The Scott 
branch 












The effect of mouse strain on hind limb ischemia model 
Besides BALB/c, many other mouse strains have been used for the murine hind 
limb ischemia model. The strain-dependent response has long been recorded 
and studied. The most often compared strains in the hind limb ischemia model 
are BALB/c and C57BL/6. C57BL/6 mice have been shown to have a faster 
recovery and a lower degree of necrosis compared to the BALB/c strain in the 
hind limb ischemia model (Fukino, Sata, Seko, Hirata, & Nagai, 2003; Helisch 
et al., 2006; Potter, 1985). Several factors have been identified for this strain-
dependent response. One of them is the difference in pre-existing collateral 
vessels structure. BALB/c and A/J mice strains have fewer intrinsic collateral 
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vessels in the hind limb compared to the C57BL/6 strain (Chalothorn & Faber, 
2010; Helisch et al., 2006; Zbinden et al., 2007). After the occlusion of the 
femoral artery, collateral vessels are able to bypass the occlusion and continue 
to supply blood to the downstream tissue, therefore reducing the ischemic 
burden and tissue damage. 
In addition, Marques et al. (2011) found that BALB/c and C57BL6 mice differ 
in their inflammatory response in the angiogenesis process. Following a 
subcutaneous sponge implant, BALB/c have higher neutrophil recruitment and 
activation compared to the C57BL/6J mice, while C57BL/6J mice produced 
more MCP-1, and had a higher vascular density in the sponge implant. A 
quantitative trait locus on chromosome 7 of C57BL/6 has been identified 
(Barone, Knudsen, Nelson, Feuerstein, & Willette, 1993; Dokun et al., 2008) to 
be necessary for tissue preservation in the hind limb ischemia model. The exact 
genes responsible remain unknown.   
The effect of BALB/c substrain selection on hind limb ischemia 
model  
The differences between mouse strains can be substantial, but how much do 
these substrains, within the same strain, differ from each other? 
There is limited literature comparing the different BALB/c substrains in terms 
of angiogenesis and their performance in hind limb ischemia model. One piece 
of indirect information was reported in Anderson, Wax, and Potter (1985), who 
studied plasmacytomas induced in different substrains of BALB/c mice 
following Pristane oil injection. Pristtane-induced mouse plasmacytoma, or 
plasma cell malignancy, is a model for human multiple myeloma (Gado, Silva, 
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Paloczi, Domjan, & Falus, 2001). It is characterized by chronic inflammation, 
polypoid lesions, increased angiogenesis, and malignant B-cells and B-cells-
derived plasma cells (Anderson, et al., 1985). All substrains except for 
BALB/cJ developed plasmacytomas following Pristane injection. BALB/cAnPt 
(Andervont branch) quickly developed large, leaky vessels (Anderson, et al., 
1985). They also had a persistant inflammatory response and angiogenesis up 
to day 12, while BALB/cJ (Scott branch) showed limited angiogenesis in day 
4-8 and a regression of new vessels afterwards (Anderson, et al., 1985).  
Besides that, the effect of substrains on mice response to surgically induced hind 
limb ischemia is rarely documented. A systematic comparison of different 
BALB/c substrains used in the murine hind limb ischemia model is difficult, 
because often the substrain used is not reported, due to a lack of standardized 
readout for inter-study comparison. Therefore, a large part of data in this section 
is obtained through personal communication with the authors and the animal 
providers.  
Methods 
Database and search strategy 
Pubmed and Embase were used to search for all relevant studies up to 13th July, 
2016. The following search terms were used for Pubmed: ("mice, inbred balb 
c"[MeSH Terms] OR "inbred balb c mice"[All Fields] OR "balb c"[All Fields]) 
AND ("lower extremity"[MeSH Terms] OR ("lower"[All Fields] AND 
"extremity"[All Fields]) OR "lower extremity"[All Fields] OR "hindlimb"[All 
Fields] OR "hindlimb"[MeSH Terms]) AND ("ischaemia"[All Fields] OR 
"ischemia"[MeSH Terms] OR "ischemia"[All Fields]), or ("mice"[MeSH 
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Terms] OR "mice"[All Fields] OR "murine"[All Fields]) AND ("lower 
extremity"[MeSH Terms] OR ("lower"[All Fields] AND "extremity"[All 
Fields]) OR "lower extremity"[All Fields] OR "hindlimb"[All Fields] OR 
"hindlimb"[MeSH Terms]) AND ("ischaemia"[All Fields] OR 
"ischemia"[MeSH Terms] OR "ischemia"[All Fields]) AND ("mice, inbred balb 
c"[MeSH Terms] OR "inbred balb c mice"[All Fields] OR "balb c"[All Fields]) 
AND ("mice, nude"[MeSH Terms] OR ("mice"[All Fields] AND "nude"[All 
Fields]) OR "nude mice"[All Fields] OR "nude"[All Fields]). The following 
search terms were used for Embase: balb AND c AND limb AND ischemia, 
balb AND c AND hindlimb AND ischemia, balb AND c AND nude AND limb 
AND ischemia, balb AND c AND nude AND hindlimb AND ischemia. 
Selection criteria 
The following criteria were used to select for eligible studies: (1) The article is 
written in English.  (2) The article is an original research article. (3) The animal 
model of murine hind limb ischemia was used. (4) Either wildtype (nondiabetic 
or transgenic) BALB/c or BALB/c nude mice were used in the study. (5) The 
study contains vehicle or sham control (6) There is minimally 2 weeks of 
follow-up. (7) The substrain of BALB/c or BALB/c nude mice can be identified. 
(8) The reported outcome includes degree of tissue necrosis for the vehicle/sham 
control mice. 
Data analysis 
The degree of necrosis was chosen as the parameter for inter-study comparison. 
Some studies reported the degree of toe, foot, or limb necrosis, while other 
studies used a semi-quantitative scoring system. In order to standardize the 
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scoring, the following simplified scoring system is used: 0, no necrosis; 1, toes 
necrosis; 2, foot necrosis; 3, limb necrosis.  
Results 
A total of 486 publications were identified. 3 studies were excluded because 
they were not in English. 95 studies were excluded because they were not 
original research articles. 141 studies were excluded because they did not use 
the murine hind limb ischemia model. 22 studies were excluded because they 
used mouse strains other than BALB/c or BALB/c nude, or that they used 
transgenic mice, or that they did not identify the strain of animal used. 4 studies 
were excluded because they did not have a minimum of 2 weeks of follow-up. 
2 studies were excluded because the full text could not be retrieved. After 
removing the duplicates, 166 publications were identified as relevant.  
Among the 166 publications, 116 publications (67%) specified the name of the 
animal provider, while only 16 publications (10%) specified the name of the 
substrain used. From searching through the company website and personal 
communication, I was able to confirm the substrain in 46 studies. A list of the 
46 studies can be found in Annex B. 26 of these studies did not provide 
quantitative data on the degree of necrosis of the animals, and in Blocki, Wang 
et al. (2015), animals with foot necrosis were sacrificed before endpoint due to 
IACUC regulations. These 27 studies were therefore excluded.  
Finally, 19 studies had a vehicle-treated/sham control group, and specified their 
degree of necrosis from week 2 onward. They are listed in Table 4. Among the 
19 studies, 8 used BALB/c mice, and 11 used immunocompromised BALC/c 
nude mice. 2 studies used mice from the Scott branch, 9 used mice from the 
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Andervont branch, 7 used mice of BALB/cA substrain, and 1 study used 
BklNbt:BALB/c/nu/nu mice from Nara Biotech, Korea.  
Following a simplified scoring system (0, no necrosis; 1, toe necrosis; 2, foot 
necrosis; 3, limb necrosis), the two Scott studies had a necrosis score of 0 to 1, 
the Andervont studies scored from 1.6 to 3, the BALB/cA study from 0.3 to 2.7, 
depending on the surgical approach used, and the BklNbt:BALB/c/nu/nu study 
reported 100% amputation and therefore a score of 3. Due to the low number of 
publications, statistical analysis of the study outcome could not be conducted.  
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Table 5. Summary of review results. A: Artery. V: Vein. D.F.A,: Deep femoral artery. E.I.A.: 
External iliac artery. F.A.: Femoral artery. I.A.: Iliac artery. S.A.: Saphenous artery. S.A.B.: 
Saphenous artery branching point. Scoring system: 0, no necrosis; 1, toe necrosis; 2, foot 
necrosis; 3, limb necrosis. 
 




Even though this systematic review identified a large number of studies (166), 
using BALB/c mice in the murine hind limb ischemia model, it was difficult to 
identify the substrains of the animals used. Only 10% of the publications 
reported the substrains in the materials and methods, and another 57% provided 
only the name of the animal supplier. Because a number of large global 
companies (Jackson Laboratories, Charles River Laboratory, Envigo) offer 
more than one BALB/c or BALB/c nude substrain, it was not clear which 
animals were used in the studies. On the other hand, the smaller, regional 
institute and animal suppliers often do not have publicly available information 
on their animal stocks.    
A second difficulty in conducting a systematic comparison is the variation in 
how the study outcome was measured. The readout from the most common 
method, Laser Doppler Imaging, is dependent on the instrument used, the setup, 
and the choice of ROI. Therefore, the degree of necrosis was chosen as an 
equipment-independent parameter. However, about half of the studies did not 
report the degree of necrosis, even if occurrence of necrosis could be seen from 
some representative animal images or Laser Doppler Imaging pictures. This 
may potentially introduce bias in this review, since studies tend to report degrees 
of necrosis only when there is a positive result. 
Although the number of publications are not sufficient to confirm if the BALB/c 
mice derived from the Scott branch are more resistant to surgically induced hind 
limb ischemia, the result is still interesting. Studies using the Andervont branch 
mice all reported high necrosis scores and occurrences of limb amputation. On 
the other hand, of the two studies found using BALB/c from the Scott branch 
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(Zhou et al., 2012; Dilip et al., 2016), both reported low rates of necrosis that 
was limited to the foot level. These results are consistent with our observation 
that the Andervont branch mice (first batch of animal experiments) had a much 
higher rate of necrosis and more severe necrosis compared to the Scott branch 
mice (second batch of animal experiments).   
The animals used in both Scott studies as well as in our second batch of animal 
experiments were from the LAC branch (derived from BALB/cJ substrain in 
1955). It is unknown how closely related the BALB/cJ mice are today to the 
LAC branch after 60 years of separation (Figure 21). Ryan et al. (2016) used 
BALB/cJ mice in their study, which was not eligible for the systematic review 
because of the short follow-up time (1 week). They reported severe necrosis (30% 
toe necrosis, 40% foot necrosis, and 20% thigh or whole limb necrosis) at day 
7 after ligation and excision of femoral artery. It is possible that the BALB/cJ 
mice have similar susceptibility to ischemia as the Andervont branch, while the 
LAC branch is more resistant. However, more evidence is needed to support the 
hypothesis.  
Two studies in particular highlighted the substrain-dependent response in the 
MHI model. Thomas et al. (2016) and Goto et al. (2006) compared several 
surgical approaches in BALB/cOlaHsd-Foxn1nu (Scott branch) and 
BALB/cAJcl, respectively. Dissecting both the femoral artery and vein resulted 
in 50% of foot necrosis in Thomas et al. (2016), but only 50% toe necrosis in 
Goto et al. (2006). On the other hand, dissecting of the external iliac artery 
resulted mainly in toe necrosis in Thomas et al. (2016) (score 0.5), but produced 
70% limb amputation in Goto et al. (2006) (score 2.4). Therefore, a mild 
ischemia model in one study may become a severe model in another. This 
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drastic difference is more likely due to the substrain difference, rather than the 
immune status of the mice. Immunocompromised mice have been reported to 
have impaired recovery in the MHI model, but the BALB/c nude mice in 
Thomas et al. (2016) experienced milder necrosis for most surgical approaches 
compared to the BALB/c immune-competent mice used in Goto et al. (2006). 
Interestingly, moving further proximally and dissecting the iliac artery did not 
result in any necrosis after 3 weeks in Thomas et al. (2016), suggesting that 
there are probably strong collateral networks that bypass the cut and feed the 
downstream vessels (external iliac artery or femoral artery).  
Most genetic background comparison of the BALB/c substrains were performed 
on BALB/cJ (Scott branch) and one of the Andervont branch substrains, 
because BALB/cJ has been reported to be markedly more aggressive than its 
sister substrains. In the 1970s and 1980s, a number of studies were conducted 
to highlight the difference between the BALB/cJ substrain (Scott branch) and 
the other BALB/c substrains. Ciaranello et al. (1974) first reported the 
difference between BALB/cAn (Andervont branch) and BALB/cJ (Scott 
branch). They also observed that BALB/cJ produced high levels of certain 
enzymes, such as tyrosine hydroxylase, dopamine a-hydroxylase, and phenyl 
ethanol amine N-methyl transferase (Ciaranello, Lipsky, & Axelrod, 1974). 
Rogers, Galetto, Matthai, and Potter (1985) studied the Qa2 gene on the MHC 
locus on the chromosome 17. BALB/cJ mice again stood out among other 
substrains. BALB/cJ mice (Scott branch) and their derivatitives are Qa2a, while 
BALB/cAn (Scott branch) BALB/c are Qa2b. Furthermore, BALB/cJ mice had 
a up to 10 times higher levels of alpha-fetoprotein (AFP) compared to other 
BALB/c substrains. AFP expression is shown to be linked to the gene raf-1. 
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BALB/cJ carries the Raf-1b allele, while the other substains carry the dominant 
Raf-1a allele (Blankenhorn, Wax, Matthai, & Potter, 1985; Olsson, Lindahl, & 
Ruoslahti, 1977).  
More recently, Velez, Sokoloff, Miczek, Palmer, & Dulawa (2010) reported 
differences in genomic deletions or duplications in BALB/cJ and BALB/cByJ, 
but were unable to verify previously reported SNPs. Sittig et al. (2014) reported 
that the difference in aggressiveness between BALB/cJ and BALB/cByJ may 
not be stable or may be due to epigenetic factors. Since Sittig et al. focused on 
animal behaviour study, it is not known if similar inconsistency exists in terms 
of the mice’s angiogenesis capacity and murine hind limb ischemia model 
outcome. Within the Scott branch, there may also be differences between the 
sister substrains BALB/cJ and BALB/cOlaHsd.  
BALB/c and C57BL/6 strains are known for having different collateral densities 
and for responding differently in ischemic models. Genetic studies have reveals 
several genetic differences that may contribute to their different susceptibility 
in ischemia models. Several independent studies reported that a locus on 
chromosome 7 is responsible for up to 50% of the vasculature differences 
(Keum & Marchuk, 2009; Wang, Zhang, Wiltshire, Sealock, & Faber, 2012). 
Chromosome 8 has also been reported to contain locus linked to the collateral 
differences (Chu, Keum, & Marchuk, 2013; Sealock, Zhang, Lucitti, Moore, & 
Faber, 2014). The exact genetic mutations responsible has not been confirmed. 
The differences we observed between the two BALB/c substrains were 
comparable to that between the BALB/c and C57BL/6 mice in our hands in a 
parallel set of experiment. Therefore, it is worth investigating if the reported 
chromosome locus differs among the BALB/c substrains as well.   




It is clear that there is a significant difference in the genetic background and 
characteristics of the Andervont branch BALB/c mice and the Scott branch 
BALB/c mice. The available literature suggests that the Andervont BALB/c 
mice frequently suffer limb or foot loss following surgically induced hind limb 
ischemia, while the Scott BALB/c mice show milder and less frequent necrosis. 
However, due to the limited reports available, more evidence is needed to 
confirm the hypothesis.  
This difference between animals within the same strain can result in unexpected 
experimental results. In my case, as we optimized the surgical procedure for the 
less ischemia-resistant Andervont BALB/c mice in the first batch of animal 
experiments, the Scott BALB/c in the second round did not respond, leaving a 
very narrow therapeutic window.  
Awareness and better documentation of the different BALB/c substrains are 
essential for the reproducibility of the murine hind limb ischemia model. A 
comparative study of the angiogenesis capacity and vasculature of the 
Andervont BALB/c and the Scott BALB/c will provide useful insights on the 
implication of substrain in the hind limb ischemia model, as well as on the 
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Despite the genetic difference (described in Chapter 3) between the two batches 
of animals used, we still observed significant functional improvement in 
animals receiving BDAC treatment in both batches.  
In the first batch of animal experiments (12th Mar.– 27th Apr. 2014, substrain 
C.Cg/AnNTac-Foxn1nuNE9, Andervont branch), BDAC treatment accelerated 
revascularization at early time points after the induction of hind limb ischemia, 
as seen from the higher vessel volume measured by MRA at week 1. A single 
BDAC injection rescued most animals from tissue necrosis and loss of limb 
function (Figure 10). In the second batch of animal experiments (29th Aug. 
2014- 3rd Feb. 2015, substrain BALB/cOlaHsd-Fox1nu, Scott branch), due to 
the different substrain used, the animals intrinsically recovered faster, and no 
difference could be seen between different treatment groups in terms of 
revascularization speed (Figure 14). Yet, we observed improvement in the 
BDAC-treated animals in terms of functional recovery. The BDAC-treated 
animals started to regain grabbing function of their paws one week ahead of the 
two other treatment groups. At week 2, four out of nine BDAC-treated animals 
were able to grab with toes of their operated limbs, while only one animal from 
the monocyte- or vehicle- group were able to do so (Figure 15). 
This prompted the question: Is angiogenesis and revascularization the only 
mechanism through which BDACs exert a healing effect in the murine hind 
limb ischemia model? The significant functional improvement despite similar 
vascularization in the BDAC-treated group in the second animal experiment 
suggested that there are other mechanisms for BDACs’ therapeutic effect. 
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Summary and scope of Chapter 4 
This chapter explores alternative mechanisms of BDACs’ therapeutic effect. 
Following up the work in Chapter 2, we performed further histological analysis 
and compared tissues from different treatment groups. Two observations were 
made: Firstly, BDACs seem to reduce tissue necrosis in both batches of animal 
experiments. Secondly, BDACs promoted proliferation of ischemic tissue, and 
it was not restricted to endothelial cells. I therefore hypothesized that besides 
angiogenesis, BDACs rescue muscle cells from ischemic damage in the 
murine hind limb ischemia model through:  
a) Protecting myocytes against ischemia-induced cell death 
b) Promoting myoblast proliferation 
We tested the hypotheses using a myoblast cell line, C2C12. The effect of 
BDAC co-culture or BDAC-conditioned medium were analyzed in two in vitro 
assays: An apoptosis assay using C2C12-derived myotubes, and a proliferation 
assay using C2C12 myoblasts.  
I designed the experiments and performed the histological analysis, the in vitro 
assays, and data analysis. Ms. Nithya D/O Selvarajoo, a research assistant in our 
laboratory, helped with cell culture and performed the immunoblot analysis 
under my supervision.  
Materials and methods 
Murine model of hind limb ischemia 
The procedure for the murine hind limb ischemia model is described in 
Materials and Methods, Chapter 2.  
Chapter 4: BDACs may aid recovery in murine hind limb ischemia model 




The harvesting and preparation of muscle tissue for cyosection and paraffin-
embedded sections were described in Materials and Methods, Chapter 2.  
Picrosirius red staining was performed on paraffin-embedded sections as 
described previously (Perides, Tao, West, Sharma, & Steer, 2005). Picrosirius 
red solution was made by dissolving Sirius red F3B (C.I. 35782) in saturated 
picric acid at 1g/L. The solution was filtered before use. Acidified water was 
prepared by diluting glacial acetic acid in double distilled water at 1:200 (v/v). 
After dewaxing and hydrating the paraffin-embedded sections in xylene and 
ethanol, the slides were rinsed in double distilled water before being stained 
with Weigert’s hematoxylin for 8 minutes. The slides were washed in tap water 
and then stained with Picrosirius red solution for one hour at room temperature. 
They were then washed three times in acidified water and once in double 
distilled water. The slides were dehydrated in ethanol and xylene before being 
mounted in a xylene based medium for microscopy. Fibrosis area quantification 
was performed using ImageJ software (Rasband, 1997-2016). 
Tissue damage was evaluated using H&E staining. Tissue damage is defined by 
the presence of adipo-replacement, mononuclear cell infiltration, or fibrosis 
(Miranda Grounds, 2014; Zaccagnini et al., 2015).  
Immunohistochemistry staining was performed as described in Materials and 
Methods, Chapter 2. Microscopic pictures were taken with an Olympus IX71 
inverted microscope and an Olympus CP70 microscope camera.  
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Mouse myoblast cell line C2C12 (CRL-1772, ATCC, Manassas, USA) cells 
were cultured in high glucose DMEM (11965, GIBCO, ThermoFisher Scientific) 
supplemented with 20% FBS and 1% p/s. For C2C12 differentiation, C2C12 
cells were seeded at 240,000 cells per well on 24-well plates. One day after 
seeding, the medium was replaced with differentiation medium containing high 
glucose DMEM supplemented with 2% horse serum and 1% p/s. The 
differentiation medium was replaced daily for three days, and every 12 hours 
for the subsequent 2 days.   
C2C12-derived myotube apoptosis assay 
C2C12-differentiated myotubes cultured in 24-well plates were incubated in 
staurosporine solution at specified concentrations in serum-free high glucose 
DMEM supplemented with 1% p/s for 6 hours. The wells were then washed 
three times with HBSS, and the medium replaced with high glucose DMEM 
with 1% p/s. BDACs at 200,000 cells per well were added when indicated. 
Quantification of myotube detachment area was performed using ImageJ 
(Rasband, 1997-2016). 
Protein isolation and immunoblot analysis 
Cells were washed with PBS and lysed in radioimmunoprecipitation assay 
buffer on ice for 30 minutes. Immunoblot analysis was performed using 
antibodies for cleaved caspase-3 (ASP175, Cell Signaling Technology, Beverly, 
USA) at a concentration of 1:1000, and myosin heavy chain (MF 20, 
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Development Studies Hybridoma Bank, Iowa City, USA) at a concentration of 
2.6 μg/ml (1:100 dilution in 5% BSA in PBS).  
C2C12 proliferation and viability assay 
For C2C12-BDAC co-culture, C2C12 cells were seeded at 10,000 cells/well on 
24-well plates and allowed to adhere overnight in high glucose DMEM 
supplemented with 20% FBS and 1% p/s. On the next day, the C2C12 cell layer 
was starved in high glucose DMEM supplemented with 1% p/s for 6 hours. 
BDACs were then seeded on top at specified ratios in high glucose DMEM 
supplemented with 1% p/s. For conditioned medium, BDAC cell layer was 
washed three times with HBSS, and then incubated in high glucose DMEM 
supplemented with 1% p/s. For C2C12 viability assay, BDAC-conditioned 
medium was harvested after 24 hours, filtered through 0.45μm syringe filters 
and centrifuged at 1,000 g for 10 minutes. C2C12 cells were seeded at 10,000 
cells/well on 48-well plates and allowed to adhere for 6 hours in high glucose 
DMEM supplemented with 1% p/s. The medium was then replaced with 
BDAC-conditioned medium or high glucose DMEM supplemented with 1% p/s.  
AlamarBlue cell viability assay 
AlamarBlue Assay was performed according to the manufacturer’s instructions. 
In brief, cells were cultured on 48-well plates. The cell culture medium was 
aspirated and 200 μL of the original medium was added back to each well. 20 
μL of alamarBlue reagents were added immediately to each well and gently 
mixed. The plates were incubated for four hours. The cell medium was 
transferred to a 96-well plate and the fluorescence signal (excitation: 540-570 
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nm; emission: 580-610 nm) was recorded using a plate reader (PHERAstar, 
BMG Labtech, Ortenberg, Germany). 
Statistical analysis 
Statistical analysis was performed using R version 3.3.0 (R Development Team, 
2016). Mann-Whitney-Wilcoxon test (Mann & Whitney, 1947) was used to 
compare mean semi-quantitative H&E scoring. A p value of less than 0.05 was 
considered statistically significant.  
Results  
The BDAC-treated animals showed less tissue damage in both batches of 
animal experiments 
We examined whether there were other physiological changes besides 
angiogenesis after BDAC-treatment. In the first batch of animal experiments, 
BDAC injection rescued most mice from toe or limb necrosis. We took a closer 
look at the morphology of the gastrocnemius muscle (calf), one of the hind limb 
muscles most affected by the ischemia. Histological analysis revealed fibrosis, 
neutrophil infiltration, and muscle degeneration with adipose replacement in all 
experimental animals, which indicates tissue damage. Fibre regeneration, 
characterized by muscles fibres with a centralized nucleus, was also observed 
(representative images at week 4 shown in Figure 22). In accordance with 
phenotypic changes of the lower limb, a higher degree of mononuclear cells 
infiltration and muscle degeneration with adipose replacement were observed 
in the vehicle-treated group (asterisked, Figure 22). Therefore, along with 
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accelerating revascularization, BDACs promoted muscle preservation and 
regeneration under ischemic conditions.  
 
Figure 22. BDAC-treatment reduced muscle degeneration in the first batch of animal 
experiments. Representative images from H&E staining of paraffin embedded sections of the 
calf muscles from right hind limb (the ligated one). (1) The vehicle-treated animals. (2) The 
BDAC-treated animals. *: Adipose tissue. Arrow: Mononuclear cell infiltration. Arrow head: 
Fibrosis. (1), (2): scale bar represents 500μm. A-F: scale bar represents 100μm. Data published 
in Blocki, Wang et al. (2015).  
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It is not certain, however, whether the decreased tissue damage is due to 
improved perfusion (that in turn improved tissue survival), as observed in MRA 
(described in Chapter 2), or due to direct interaction between BDACs and 
muscle tissue.  
We proceeded to examine the muscle tissue harvested from the second batch of 
animal experiments, where no significant difference in revascularization 
between the treatment groups was observed (Chapter 2). Although animals from 
the second batch of experiments showed almost complete perfusion recovery by 
week 1 or 2 from MRA and Laser Doppler Imaging analysis, muscle 
degeneration and damage were observed in all treatment groups. At week 1, the 
vehicle-treated group from the second batch of animal experiments showed 
more fibrosis areas, mononuclear cell infiltration, and adipo-replacement 
compared with the monocyte- and BDAC-treated group. This difference 
decreased with time. However, due to the small sample size, a semi-quantitative 
histology scoring did not reveal statistical differences between the treatment 
groups (Figure 23).  
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Figure 23. The BDACs and vehicle-treated groups showed less muscle degeneration at 
week 1 in the second batch of animal experiments. Control: Unoperated hind limb (left 
hind limb). Vehicle, monocyte, and BDAC: Operated hind limb (right hind limb) of animals 
from the respective treatment groups. Top: Representative images from at least three 
animals are shown. Bottom: Muscle sections were graded on a score from 0 to 3. 0: Normal. 
1: Mild. 2: Moderate. 3: Severe. Averages per treatment group were shown. Statistical 
analysis was performed using Mann-Whitney-Wilcoxon test. No significant difference was 
observed at any time point.  
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To further evaluate the infiltrating mononuclear cell population, iNOS (marker 
for M1/classically activated macrophages) and CD206 (marker for 
M2/alternatively activated macrophage) staining was performed on the 
gastrocnemius muscle sections harvested in week 1 (Figure 24).  Among the 
three time points, week 1 samples were chosen for the analysis, where most 
morphological differences were observed in the H&E staining (Figure 23), 
There were no statistically significant differences between all groups in the 
percentage of CD206+ cells (F3,8 = 2.48, p = 0.135). However, in the monocyte-
treated group, the percentage of iNOS+ cells was almost 3 times that of the 
vehicle or BDAC-treated group. The difference was statistically significant (F3,8 
= 7.39, p = 0.014) (Figure 24).  
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Figure 24. Monocyte-treated animals had higher percentage of iNOS-positive cells at week 
1. Gastrocnemius muscle transverse cryosections were stained with either CD206 or iNOS, and 
whole mount image of the tissue section was used for the analysis. Percentage of cells with 
positive staining was calculated by dividing the number of positively stained cells by total dapi 
count. “All” represents the sum of the percentages of CD206+ cells and iNOS+ cells. Bar height 
represents average and error bar represents standard error. p-values were calculated using one 
way ANOVA with Tukey’s post hoc test. Scale bar represents 50 µm.  
All animals in the second batch of animal experiments showed limited muscle 
tissue fibrosis 
We further investigated the degree of fibrosis in gastrocnemius muscles using 
picrosirius red staining. Picrosirius red staining allows for visualization of 
collagen fibres. Under light microscopy, the collagen fibres appear red, while 
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the muscle fibres and cytoplasm appear yellow. The nuclei are counter-stained 
black with Weigert's hematoxylin staining.  
The degree of fibrosis in all treatment groups appeared similar, and the fibrosis 
areas were in general below 5%. Statistical analysis showed no significant 
difference between the treatment groups (One way ANOVA, F3,8 = 1.92, F3,15 
= 1.33, F3,26 = 1.35; p = 0.21, 0.30, 0.28; for week 1, week 2, week 3, 
respectively) (Figure 25).  
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Figure 25. Limited fibrosis in the second animal experiment. At pre-determined time points, 
gastrocnemius muscles were harvested, fixed with para-formaldehyde, and embedded in 
paraffin. The middle sections were used for picrosirius red staining. The nuclei were counter-
stained with Weigert’s hematoxylin. Top: Representative light field macroscopy images are 
shown for each treatment group at the end of week 1, 2, and 3. Red: Collagen fibres. Yellow: 
Muscle fibres and cytoplasm. Black: Nuclei. Bottom: Quantification of fibrosis area. Samples 
from at least three animals were analysed per treatment group per time point. Bar height 
represents average percentage fibrosis area over total muscle section area. Error bar represents 
standard error. Statistical analysis was performed using one way ANOVA.   
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More than endothelial cells proliferated in the ischemic gastrocnemius 
muscle  
Besides protecting muscle tissue from apoptosis/necrosis, BDACs may also 
improve tissue recovery after ischemic damage by promoting cell proliferation. 
The primary hypothesis of this thesis is that BDACs protect endothelial cell 
angiogenesis (Hypothesis, page 29). Therefore, the proliferation of endothelial 
cells was examined by a co-staining of CD31, an endothelial cell marker, and 
Ki67, a proliferating cell marker. The gastrocnemius muscles from the second 
animal experiment were used because, only in this batch, muscle samples were 
harvested at intermediate time points. If BDACs indeed act mainly by 
promoting angiogenesis, an increased co-localization of Ki67 with CD31 
positive capillaries should be observed.  
At week 1, contrary to our expectation, more Ki67-positive cells were observed 
in the vehicle-treated group than the BDAC and monocyte-treated group (Figure 
26). Most of the Ki67 staining also did not co-localize with CD31 staining, but 
was located in between muscle cells. The few Ki67/CD31 positive cells tend to 
be located on large blood vessels.  
At week 2, the number of Ki67-positive cells decreased in the vehicle-treated 
group. Meanwhile, we started to observe some Ki67-positive cells in the BDAC 
and monocyte-treated group. Again, some of these Ki67-positive cells co-
localized with large blood vessels and, less frequently, with capillaries, while 
most of them were located in between muscle cells.  
Immunohistochemistry staining at week 3 showed that the BDAC-treated 
animals seemed to have a higher number of Ki67-positive cells. Ki67-positive 
cells were found both in between muscle cells and co-localizing with CD31-
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positive endothelial cells. Very few Ki67-positive cells were seen in monocyte 
and vehicle-treated groups at week 3.   
The partial co-localization between Ki67 and CD31 staining indicated that other 
cell types besides endothelial cells were proliferating after the induction of 
ischemia.  
 
Figure 26. The expression of CD31 (red) and Ki67 (green) do not always co-localize in the 
gastrocnemius muscle. Representative merged CD31/Ki67/DAPI images are shown for 
Control group (left/unoperated hind limb) and BDAC, monocyte, and vehicle-treated groups 
(right hind limb). Arrows: Co-localization of Ki67 staining with large blood vessels. Arrow 
heads: Co-localization of Ki67 staining with capillaries.  
BDAC co-culture improved the recovery of C2C12-derived myotubes from 
staurosporine-induced apoptosis in vitro  
Based on the observation that BDACs reduced the extent of tissue damage in 
vivo, we investigated if BDAC co-culture is able to protect mature muscle cells 
from apoptosis in vitro, using a well-established myocyte cell line C2C12. 
C2C12 were differentiated into mature myotubes. To induce myotube apoptosis, 
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we used staurosporine (STS), a kinase inhibitor. Staurosporine is widely used 
in apoptosis research because of its ability to activate caspase-3, one of the main 
apoptosis effector molecules. Under normal circumstances, caspase-3 exists in 
its un-cleaved and inactivated form, procaspase-3. Upon activation, caspase-3 
will be cleaved into fragments. The bigger fragments are 17 kDa and 19 kDa, 
which can be detected by an anti-cleaved capspase-3 antibody. In addition, we 
also measured the level of myosin heavy chain protein (MF20), which is 
expressed in mature myotubes, and provides an estimation of the amount of 
remaining mature myotubes after staurosporine treatment.   
STS treatment led to significant morphology changes in C2C12-derived 
myotube (Figure 27). Immediately after STS treatment (0h), the myotubes 
started disintegrating and floating dead cells were present in both 2μM and 
10μM STS-treated wells. After 8 hours, there was a further loss of structure in 
all conditions. Furthermore, the myotubes treated with 10μM STS started to 
detach from the cell culture plate. In the cells co-cultured with BDACs, however, 
there were fewer areas of cell detachment (arrows, Figure 27). Quantification 
of percentage of myotube detachment areas shows that at 8 hours, co-culture 
with BDAC significantly reduced cell detachment compared to cells treated 
with the same concentration of STS (10 µM) (one way ANOVA, F2,6 = 8.68, p 
= 0.017). 
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Figure 27. BDAC co-culture reduces C2C12-derived myotube detachment after STS 
treatment. Top: Bright field microscopy images of C2C12-derived myotubes. Experiments 
were conducted in serum-free high glucose DMEM. C2C12 myoblasts were differentiated into 
mature myotubes, and were then incubated with stautosporine (STS) at indicated concentrations 
for 6 hours. After 6 hours, the cell layer was either harvested for Western blot analysis (0h), or 
washed and changed to fresh medium with or without co-culture with BDACs. The cell layer 
was harvested after another 8 hours of incubation (8h). Arrows: Areas of cell detachment. Scale 
bar represents 500µm. Bottom: Quantification of percentage of myotube detachment area in 
field of view. Bar height represents average of three samples. Error bar represents standard 
deviation. p-value was calculated using one way ANOVA.  
We measured the level of myosin heavy chain and cleaved-caspase-3 by 
immunoblotting analysis (Figure 28). Immediately after STS treatment (0h), 
C2C12 myotubes expressed STS dose-dependent amounts of cleaved caspase-
3, while the expression of MF20 dropped drastically to almost zero. After 
recovering in STS-free fresh medium for another 8 hours (8h), the amount of 
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cleaved caspase-3 decreased. The BDAC-treated cells expressed slightly less of 
the 19kDa caspase-3 fragment compared to the non-BDAC-treated cells. The 
BDAC-treated cells also expressed a higher level of MF20, indicating a larger 
number of recovered myotubes (red box, Figure 28). The experiment would 
need to be repeated in order to confirm the difference.  
 
Figure 28. BDAC co-culture increases the recovery of myosin heavy chain expression. A: 
Western blot analysis of cell layers from Figure 24 using myosin heavy chain antibody MF 20 
and anti-cleaved caspase-3. β-actin was used as the loading control. B, C, D: Densitometry 
analysis for MF 20 and the 19kDa/17kDa fragments of cleaved caspase-3, values normalized 
against β-actin. x-axis represents the concentration of staurosporine (STS). Red rectangle: The 
condition with BDAC co-culture seemed to have higher level of myosin heavy chain expression 
than the one without, as detected by MF 20. The experiment was performed only once.  
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BDAC co-culture and conditioned medium promoted C2C12 myoblasts 
proliferation in a dose-dependent manner 
One of proliferating population in damaged muscle is satellite cells, which 
remain quiescent in normal conditions, and become activated upon muscle 
injury, differentiating into proliferating myoblasts (Cornelison & Wold, 1997). 
To investigate the effect of BDACs on myoblast proliferation, we observed the 
proliferation of C2C12 myoblasts either in direct co-culture with BDACs or in 
BDAC-conditioned medium.  
In the direct co-culture experiment, the addition of BDACs increased C2C12 
cell number in the first 24 hours in a dose dependent manner (Figure 29), with 
the highest C2C12 confluency at a C2C12: BDAC ratio of 1:10. However, after 
48 hours of co-culture, the cell number decreased, probably due to the 
exhaustion of nutrient in the serum-free medium. The data have not been 
quantified.  
 
Figure 29. BDAC co-culture promotes C2C12 cell proliferation. Representative phase 
contrast images of BDAC-C2C12 myoblast co-culture in serum-free high glucose DMEM 
medium. C2C12 cells were seeded at 10,000 per well on a 24-well plate (5.3x103 cells/cm2), 
and BDACs harvested after 5 days of ex vivo culture were seeded on top of C2C12 cells the day 
after at different C2C12-BDAC ratios. Top: 24 hours after BDAC seeding. Bottom: 48 hours 
after BDAC seeding.  
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When BDAC-conditioned medium is added to C2C12 cell culture at different 
percentages, there was a dose-dependent increase in C2C12 cell viability 
compared to control, as measured by alamarBlue assay (Figure 30). This effect 
was still significant at 48 hours after seeding, even though the cell number per 
well decreased in all conditions, probably due to serum starvation (Figure 30)  
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 Figure 30. BDAC-conditioned medium improved C2C12 cell viability in serum-free 
condition. The experiment was conducted in serum-free high glucose DMEM medium. Top: 
representative phase contrast images of C2C12 cells at 24 hours after seeding. C2C12 cells were 
seeded at 104 cells per well on 48-well plate, or 10.5x103 cells/cm2. Bottom: alamarBlue (AB) 
reduction measurement was performed immediately after seeding (0h), after 24 hours (24h), 
and after 48 hours (48h). Representative data from three experiments are shown. Bar height 
represents average fluorescent signal in relative fluorescent units (RFU). Error bar represents 
standard error. p-value was calculated using one way ANOVA.  
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The results presented in this chapter support the hypothesis that BDACs may 
have functions other than promoting angiogenesis, such as protecting myocytes 
from ischemia induced damage and promoting myogenic cell proliferation.  
The first hint of BDACs’ possible tissue protective role came from histological 
analysis. Besides a BDAC-associated reduction in adipo-replacement, we also 
observed less mononuclear cell infiltration at week1, even though BDACs 
secrete high levels of monocyte chemoattractant in vitro, such as GM-CSF and 
MCP-1 (Blocki, Wang et al., 2015). It is possible that BDACs have a protective 
effect on the muscle tissues against ischemic damage and endogenous chronic 
inflammation.  
From H&E staining, we observed increased mononuclear cell infiltration in 
both vehicle and monocyte-treated group compared to BDAC-treated group. 
However, at week 1, iNOS-positive cells were increased only in the monocyte-
treated group, and CD206 staining was similar in all treatment groups. It is 
possible that the infiltration observed in vehicle-treated group is due to 
neutrophils or monocytes that are not captured by iNOS or CD206 staining. 
Tissue degeneration and regeneration is a complex process involving an 
interplay of various cell types, such as progenitor cells, endogenous immune 
cells, fibroblasts, pericytes, among others (Blaisdell, 2002; Karalaki, Fili, 
Philippou, & Koutsilieris, 2009). In vitro assays provide a way to break down 
the system to simpler parts. We chose to first focus on myocytes, which make 
up most of the tissue mass, and directly account for the hind limb functionality. 
We observed that when apoptotic C2C12-derived myotubes were co-cultured 
with BDACs, the level of caspase-3 19kDa fragments was only slightly lower 
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compared to the control, and there was no effect on caspase-3 17kDa fragments. 
However, there was an increase in the level of myosin heavy chain. Dumont and 
Frenette (2010) reported a similar effect. After incubating with apoptotic 
neutrophils, macrophages preserved MHC expression in apoptotic C2C12. This 
effect was reduced by an antibody to insulin-like growth factor-1 (IGF-1). IGF 
promotes myoblasts proliferation and differentiation (Coolican, Samuel, Ewton, 
McWade, & Florini, 1997). It is reported that IGF is essential for macrophage-
mediated muscle repair (Lu et al., 2011; Tonkin et al., 2015). It seems that 
although BDAC co-culture did not prevent activation of caspase-3, it did 
accelerate the recovery of C2C12 myotubes. 
We observed that BDAC co-culture as well as BDAC-conditioned media 
resulted in higher C2C12 cell number in a serum-free medium, suggesting a role 
in maintaining cell proliferation or in reducing C2C12 cell death under staving 
challenge. Chazaud et al. (2003) reported that monocytes promoted myogenic 
cell proliferation in a paracrine manner. On the other hand, Sonnet et al. (2006) 
reported that macrophages reduce apoptosis of myoblasts through adhesion 
molecules. Whether this is the case for BDACs still needs to be verified.  
Several mechanisms have been suggested for interactions between monocyte-
derived cells and myocytes/myogenic cells. Myogenic cells secrete monocyte 
chemoattractant such as MCP-1, CX3CL1, VEGF, urokinase plasminogen 
activator (Chazaud et al., 2003), as well as Il-4, a cytokine for alternative 
macrophage differentiation (Arnold et al., 2007). On the other hand, monocytes 
were shown to rescue myogenic cells from apoptosis through cell-cell contact 
(Chazaud et al., 2003), and to promote myogenic cell proliferation and 
differentiation (Arnold et al., 2007). Another factor worth considering is MMP9, 
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which is abundantly secreted by BDACs in vitro (Blocki, Wang, et al., 2015). 
Mixed results of MMP9’s effect on muscle repair have been published. Besides 
its role on angiogenesis, MMP9 has been shown to contribute to reduced tissue 
damage (Meisner, Annex, & Price, 2015). On the other hand, others reported 
that MMP9 inhibition promotes myogenic cell proliferation (Hindi, Shin, Ogura, 
Li, & Kumar, 2013). 
It is curious how BDACs have an effect on both endothelial cells/angiogenesis, 
as well as on myogenic cells/muscle regeneration. It is possibly due to the 
plasticity of monocyte-derived cells, and that they are able to adapt to the 
environment or the other cell types present. BDACs’ intermediate phenotype 
and marker expression between macrophages and pericytes also suggest that 
they may play multiple roles in muscle ischemia. Secondly, many factors 
secreted by BDACs or other monocyte-related cell types have effect on different 
cell types. The above mentioned IGF and MMP9 are typical examples. Lastly, 
BDACs may also have additional effect through recruiting monocytes and 
influencing endogenous macrophage polarization, probably through secretion 
of cytokines such as GM-CSF and MCP-1 (Blocki, Wang, et al., 2015). 
Conclusion 
Besides promoting angiogenesis, BDACs may have additional roles in the 
rescue of ischemic tissue. Histological analysis from both batches of animal 
studies suggested that BDACs may be able to reduce tissue degeneration. 
Focusing on myocytes, we verified the muscle-protective effects of BDACs 
using C2C12-derived myotubes. In addition, BDAC co-culture seems to have 
promoted myogeneic cell proliferation.  
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The preliminary data suggested multiple effects of BDAC treatment. This 
would be beneficial in the case of CLI, where compromised perfusion, chronic 
tissue death, and impaired regeneration are concurrently present. BDAC 
treatment may help to improve the efficacy of conventional therapy, which 
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Macromolecular crowding is essential for BDAC generation 
Monocyte-derived cells may hold great potential for CLI therapy. However, this 
plastic and heterogeneous population has a wide spectrum of functions, ranging 
from inducing inflammation, phagocytosis, modulating fibrosis, to stimulating 
angiogenesis and regeneration. Generating a cell type with the desired profile 
in an efficient manner is a constant challenge whilst developing cell-based CLI 
treatment. In this thesis, by investigating the effect of MMC on BDAC 
generation, we have demonstrated that MMC not only increases the cell yield, 
but is also essential for BDAC-specific characteristics and functionality. Cells 
produced with the use of MMC had a more elongated, spindle-shaped 
morphology, expressed higher levels of angiogenesis-related and macrophage 
markers, and tended to have a stronger capacity to promote endothelial cell 
sprouting in vitro. The use of MMC did not increase the phagocytic activity of 
BDACs or the proliferation of adherent, differentiated BDACs. It is most likely 
that MMC promoted monocyte attachment and differentiation into BDACs, 
through amplifying cell-cell interaction and by modulating the fibronectin 
matrix to be more conducive for BDAC generation. In general, MMC may 
provide a platform for improving the generation efficiency and for helping to 
steer the functionality of monocyte-derived cells.  
BDACs: A promising candidate for CLI therapy 
BDACs, generated from human peripheral blood using MMC, resulted in 
significant improvement in mice recovery from a hind limb ischemia model. 
One intramuscular injection of BDACs rescued most mice (BALB/c nude, 
C.Cg/AnNTac-Foxn1nuNE9) from necrosis after surgically induced ischemia. 
BDAC treatment not only lowered the tissue necrosis rate from 71% in the 
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control group to 17%, but also significantly reduced the severity of necrosis. 
MRA analysis showed that BDACs accelerated revascularization in the 
ischemic hind limb. Therefore, BDACs indeed promoted mice recovery through 
therapeutic angiogenesis, as we hypothesized.  
To understand BDACs’ therapeutic effect in the MHI model, we compared 
BDACs and monocyte treatment in a second batch of animal experiments using 
BALB/c nude mice (BALB/cOlaHsd-Fox1nu), which turned out to be of a 
different substrain. These mice intrinsically had a much faster spontaneous 
perfusion recovery, rarely experienced necrosis, and thus left little room for 
improvement. Unlike in the previous experiment, we did not observe any 
difference in revascularization. However, even though angiogenesis was no 
longer a limiting factor, the BDAC-treated animals had a faster functional 
recovery than the monocyte and vehicle-treated group. This led us to the 
hypothesis that BDACs improve MHI outcome through additional mechanisms 
besides promoting revascularization. Our preliminary data suggested that 
BDACs may have myocyte-protective effects against ischemia induced damage, 
and may promote myogenic cell proliferation for muscle regeneration. Despite 
the substrain difference, the second batch of animal experiments demonstrated 
the robustness of BDACs’ therapeutic potential. BDACs, as a promising 
potential treatment option for CLI, merit further investigation.  
Substrain selection has a profound impact on the murine hind 
limb ischemia model outcome 
The impact of substrain is a lesson we did not expect to learn in this thesis. A 
substrain is defined by a population isolated more than 20 generations from its 
progenitors. For long-established strains like BALB/c, the separation of many 
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substrains dates back almost 80 years, resulting in substantial genetic 
differences. This includes two of the most commonly used substrains, 
BALB/cAnN and BALB/cJ.  They are the substrains of origin for our first and 
second batch of animals. The BALB/cAnN-derived mice (Andervont branch) 
showed frequent necrosis, while BALB/cJ-derived mice (Scott branch) were 
only mildly affected by the same surgical procedure. A thorough research of the 
MHI model literature revealed that the BALB/c mice substrain is often 
overlooked, and is specified in only 10% of publications. Due the scarcity of 
information, it was not possible to systematically compare the two substrains in 
terms of the MHI model outcome. Nevertheless, the two existing studies 
identified using BALB/cJ-derived BALB/c mice reported similarly a mild 
degree of necrosis following surgically induced ischemia. It is highly likely that 
the difference in substrain may indeed result in unexpectedly different 
experimental outcomes. Better documentation of the substrains in publications 
would be the first step towards understanding the implications of substrains on 
the murine hind limb ischemia model. 
Limitations of studies undertaken 
The single factor that would have made a significant difference to the outcomes 
reported in this thesis is the choice of BALB/c nude mice substrain for the 
second batch of animal experiments. The same surgical procedure induced 
substantial necrosis in the control animals from the first batch, but caused little 
or no necrosis in the second batch of animals. A wider treatment window in the 
second batch of animal experiments would have allowed us to observe bigger 
differences between the treatment groups and to gather more evidence on the 
mechanism of action of BDACs.  
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Besides that, there are several intrinsic limitations with the animal model used. 
One main criticism for the MHI model is that it involves sudden depletion of 
blood supply, while CLI is a chronic condition that develops over multiple years. 
This may result in significant differences in the inflammatory response and 
tissue degeneration.  
A second limitation with the animal model is the surgical approach used. We 
chose to cut the external iliac artery as opposed to ligation and excision of the 
entire femoral artery branch, which would have resulted in a more severe 
ischemia. CLI is a multi-level occlusion disease, with limited collateral growth 
options. Therefore, removing the entire femoral artery and ligating all side 
branches would provide a closer approximation to CLI. However, since this 
approach results in frequent limb amputation, we could not use it because of our 
IACUC regulation.  
Moreover, because immune response plays a major role in angiogenesis and 
tissue regeneration, an immunocompromised mouse model may behave 
differently from the immunocompetent ones. BALB/c nude mice do not have a 
thymus, and therefore are unable to produce T cells. Stabile et al. (2003) showed 
that T lymphocyte-deficient mice had impaired collateral growth, delayed 
functional recovery, and increased tissue necrosis and fibrosis in a murine hind 
limb ischemia model.    
In Chapter 4, in order to investigate the interaction between BDACs and 
myocytes and myocyte progenitor cells, the myoblast cell line, C2C12, was used. 
The C2C12 cell line is widely used in myocyte studies for its rapid 
differentiation into myotubes (Burattini et al., 2004). However, C2C12 
myoblasts and the derived myocytes may have different protein expression and 
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characteristics compared to primary myoblasts (Grabowska, Szeliga, 
Moraczewski, Czaplicka, & Brzoska, 2011). Another limitation of the in vitro 
model is the apoptosis inducer used, staurosporine. In critical limb ischemia and 
in murine hind limb ischemia model, tissue death is caused by a combination of 
prolonged oxygen and nutrient deprivation, accumulated toxins, and immune 
response, and can go through apoptosis, necrosis, or other cell death pathways. 
Staurosporine, on the other hand, is a protein kinase inhibitor, and activates the 
intrinsic apoptosis pathways of the treated cells. Therefore, staurosporine-
induced apoptosis is a simplified model, and is not able to represent the complex 
interactions between the factors and cell types in ischemic tissue death. A 
histological analysis of tissue death in muscle sections would provide 
supporting evidence on BDACs’ tissue protective role in ischemic conditions.  
Unanswered questions, speculations, and future work 
Building on the results presented in this thesis, some further questions on the 
mechanism of BDAC generation and action may be answered with additional 
experiments. These proposals for future work are suggested in the present 
section. With more time and resources, these experiments would complement 
the findings of this thesis.  
The effect of MMC on monocyte proliferation, adhesion, and differentiation 
We characterized the effect of MMC on the adherent population in terms of 
proliferation, marker expression, and functionality. However, BDACs derive 
from a non-adherent monocyte population and its generation requires the 
interaction of different populations in the non-adherent fraction of PBMCs.  
Since the whole PBMCs were exposed to MMC during the one-day treatment, 
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MMC may have a significant effect on the non-adherent cell population, 
especially monocytes, that contributes to BDAC generation. Characterization of 
the composition and proliferation status of the non-adherent population can 
provide valuable information on the mechanism of MMC on BDAC generation.  
This can be done conveniently by multi-colour flow cytometry.  
Does MMC function as an accelerator? 
We have always compared cells generated with or without MMC at the same 
time point. One interesting observation is that the number of adherent cells in 
the -MMC condition lags behind that of +MMC by 2 days (Figure 3). Is the 
effect of MMC to accelerate the differentiation and maturation of BDACs? If 
given more time, will cells in -MMC condition catch up in cell number, 
morphology, marker expression, and pro-angiogenic function? Following up on 
cells generated in -MMC conditions for a longer period of time may produce 
interesting results.  
The origin of BDAC and monocyte subsets 
Human blood-derived monocytes can be divided into at least three subgroups: 
classical monocytes (CD14++CD16-), intermediate monocytes (CD14++CD16+), 
and non-classical monocytes (CD14+CD16++) (Ziegler-Heitbrock et al., 2010). 
It has been proposed that each subset has its distinct characteristics and function. 
It is not clear if BDACs are derived from a specific subset of monocytes, or if 
monocytes from different subsets can be induced by the in vitro culture towards 
the BDAC phenotype. Sorting and labeling the different monocyte populations 
prior to BDAC generation (either separately or in co-culture) may provide 
insights on the source of BDACs. Transwell assays will also help to demonstrate 
                                                        Conclusion                          
146 
 
if paracrine signaling between the different monocyte subsets is important for 
BDAC generation.  
A quality control marker for BDAC 
In the spheroid sprouting assay, although all BDACs increased the cumulative 
EC sprout length, we observed some batch-to-batch variation. The fold increase 
in sprout length, compared to EC alone control, ranged from 1.3 to 2.4 times 
(Figure 9). We attempted to identify any physical characteristics of BDACs that 
might correlate with their performance in functional assays. However, we failed 
to find any correlation between the number of cells harvested or average cell 
length, and BDAC performance in spheroid sprouting assay (data not shown). 
A protein directly involved in BDAC function, such as VEGF or MMP-9, may 
be a better predictor for BDAC performance. In this thesis, we did not 
characterize the marker expression panel for all batches of BDACs. Performing 
marker characterization and functional assays in parallel will enable us to 
identify differences, if any, in protein expression that correlate with BDAC 
function. Such characteristics may serve as a predictive marker for BDACs’ 
pro-angiogenic capacity in vitro and in vivo, and eventually be used for quality 
control in the clinical application of BDACs. 
BDACs tracking in vivo  
Knowing the biodistribution of BDACs in vivo will provide valuable 
information on their function. It will enable us to find out BDACs’ relative 
position to blood vessels, their marker expression and secretion profile in vivo. 
We will also be able to investigate what other cells and tissues BDACs home 
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to. Since we did not label BDACs prior to implantation, a human cell-specific 
antibody or fluorescent in situ hybridization is needed for BDAC identification.  
Analyzing the collateral growth by MRA 
We have put a lot of emphasis on the pro-angiogenic capacity of BDACs, but 
arteriogenesis is another important mechanism that should not be overlooked. 
With MRA, we have obtained the three-dimensional distribution of blood 
vessels at different time points. Using image processing techniques, it is 
possible to analyze and quantify the amount of collateral vessel growth and 
compare the different treatment groups.    
A comparative study of the BALB/c substrains in the murine hind limb 
ischemia model 
In Chapter 3, I realized that there is an absence of literature comparing the 
angiogenesis capacity of different BALB/c substrains.  From our data, it is clear 
that differences exist and can have important impact on experimental outcome. 
The same surgical approach resulted in severe necrosis and toe/foot amputations 
in one substrain, and rarely any necrosis in another.  A comparative study of the 
BALB/c substrains’ response in the MHI model will provide valuable 
information for future studies on choosing an appropriate animal model and 
surgical approach. Substrains also provide an excellent platform for 
understanding the deciding factors between fast, necrosis-free recovery and 
auto-amputation, and may provide new insight into mechanisms underlying 
different outcomes seen in CLI patients.  
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The effect of BDACs on myotube apoptosis and myoblast proliferation 
The preliminary work described in Chapter 4 suggested several potential roles 
of BDACs in an ischemic environment besides promoting angiogenesis. One of 
them is to promote myotube survival from induced apoptosis. In vitro, although 
BDAC co-culture did not reduce the expression of cleaved caspase-3 in 
myotubes, it increased myotube expression of myosin heavy chain protein. 
Secondly, we also observed that BDAC co-culture and BDAC-conditioned 
media increased the proliferation and viability of the myoblast cell line C2C12, 
respectively. A transwell assay will help to clarify if cell-cell contact is indeed 
necessary for the observed BDAC-C2C12 interaction. Inhibition of BDAC-
secreted factors, such as MCP-1 and VEGF, or cell-cell adhesion molecules, 
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Annex A: Supplementary data 
 
Figure S1. Fibronectin is important for BDAC generation. PBMCs were cultured following 
the BDAC generation protocol. The plastic tissue culture plates were coated either with the 20 
μg/ml fibronectin following the protocol, or with one-tenth the original concentration (2 μg/ml). 
Phase contrast images were taken at 5 days after seeding. Representative images from two 
replicates are shown.  




Figure S2: BDAC generation is only possible when cell-cell contact between CD14+ and 
CD14- cells are allowed. Representative bright field microscopy images taken at day 5. All 
conditions were cultured according to BDAC generation protocol, but with different starting 
populations. CD14+ cells were purified using EasySep kit (Stemcell Technologies) by 
negative selection with magnetic beads. The remaining population was used as the CD14- 
cells. Top: Whole PBMCs, CD14+ cells alone, CD14- cells alone. Bottom: CD14- and CD14+ 
cells indirect co-culture in transwells. 
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